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NAD+ has emerged as a vital cofactor that can rewire metabolism, activate sirtuins, and maintain mitochon-
drial fitness through mechanisms such as the mitochondrial unfolded protein response. This improved
understanding of NAD+metabolism revived interest in NAD+-boosting strategies tomanage a wide spectrum
of diseases, ranging from diabetes to cancer. In this review, we summarize how NAD+ metabolism links
energy status with adaptive cellular and organismal responses and how this knowledge can be therapeuti-
cally exploited.Introduction
The importance of nicotinamide adenine dinucleotide (NAD+)
metabolism became apparent subsequent to the study of
pellagra, a disease characterized by a darkly pigmented skin
rash, dermatitis, diarrhea, and dementia, later resulting in death
(Sydenstricker, 1958). A century ago, pellagra was common in
rural areas of Europe and became an epidemic in the southern
United States (Sydenstricker, 1958). However, in 1914, Joseph
Goldberger tested whether pellagra was caused by a dietary
deficiency and discovered that substituting corn-based diets
with milk, eggs, and meat prevented and cured the condition
(reprinted essay, Goldberger, 2006). Later, Conrad Elvehjem
found that a nicotinamide (NAM)-enriched fraction from depro-
teinized liver and a sample of crystalline nicotinic acid (NA) cured
pellagra (Elvehjem, 1940). NA and NAM, collectively termed
niacin or vitamin B3, are now known as precursors for NAD+,
an essential element for all cells (Bogan and Brenner, 2008;
Chi and Sauve, 2013; Houtkooper et al., 2010a). Whereas
pellagra remains endemic in underdeveloped countries (Seal
et al., 2007), it is rare in developed countries and mostly occurs
in association with tuberculosis, malabsorption, alcoholism,
and eating disorders (Hegyi et al., 2004). Less severe niacin
deficiencies are more difficult to detect and are linked with low
metabolism, cold intolerance, and delayed brain development
(Forbes and Duncan, 1961; Williams and Dunbar, 2014).
So, what is NAD+, and why is it important? NAD+was originally
described more than 100 years ago by Sir Arthur Harden and
colleagues as a cofactor in fermentation (Harden and Young,
1906). Years later, another Nobel prize laureate, Hans von
Euler-Chelpin, identified this factor as a nucleoside sugar phos-
phate (1940 Nobel lecture; Euler-Chelpin, 1929). Yet it took
a third Nobel laureate, Otto Warburg, to isolate NAD(P)+ and
discover its key role for hydrogen transfer in biochemical reac-
tions (Warburg et al., 1935). NAD+ and NADP+ perform similar
redox functions within the cell, but the latter is more confined
to biosynthetic pathways and redox protective roles (reviewed
in Ying, 2008). Playing a vital role in energy metabolism withineukaryotic cells, NAD+ accepts hydride equivalents to form
reduced NADH, which furnishes reducing equivalents to the
mitochondrial electron transport chain (ETC) to fuel oxidative
phosphorylation. The roles of NAD+, however, have expanded
beyond its role as a coenzyme, as NAD+ and its metabolites
also act as degradation substrates for a wide range of enzymes,
such as sirtuins (Blander and Guarente, 2004; Haigis and
Sinclair, 2010; Hall et al., 2013; Houtkooper et al., 2010a).
Through these activities, NAD+ links cellular metabolism to
changes in signaling and transcriptional events. Here, we give
an overview of the current knowledge on NAD+ metabolism,
including its biosynthesis, compartmentalization, degradation,
and actions as a signaling molecule.
NAD+: Metabolic and Therapeutic Interests
Food Sources and Bioavailability of NAD+
The daily requirements for NAD+ biosynthesis can be met with
the consumption of less than 20 mg of niacin (Bogan and Bren-
ner, 2008). Four major molecules have been described as the
root substrates for different NAD+ biosynthetic pathways: the
amino acid tryptophan (Trp), NA, NAM, and nicotinamide ribo-
side (NR) (Figures 1A, 1B, and 1D). However, intermediate
compounds of these NAD+ biosynthetic pathways, such as nico-
tinamide mononucleotide (NMN), can also directly stimulate
NAD+ synthesis. Vitamin B3 deficiency occurs on low-protein di-
ets or diets relying mostly on untreated maize. Interestingly,
niacin is found in maize but is not bioavailable unless given an al-
kali treatment, a process used in Aztec andMesoamerican times
termed nixtamalization (Gwirtz and Garcia-Casal, 2014). In ani-
mal products, and probably in all uncooked foods, the NAD+
and NADP+ cellular content accounts for much of their dietary
niacin content (Gross and Henderson, 1983), yet, as exemplified
above with corn nixtamalization, their bioavailability might be
affected by food processing or cooking.
Bioavailability studies indicated that ingested NAD+ was pri-
marily hydrolyzed in the small intestine by brush border cells
(Baum et al., 1982; Gross and Henderson, 1983). As a first step,Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 31
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Figure 1. NAD+ Precursor Metabolism and NAD+-Consuming Enzymes
Trp, NA, NAM, and NR are utilized through distinct metabolic pathways to form NAD+.
(A) NAD+ synthesis fromNA, also known as the Preiss-Handler pathway, is initiated by the NAPRT, which uses PRPP to form NAMN. Together with ATP, NAMN is
then converted into NAAD by the NMNAT1–3 enzymes. Finally, NAAD is transformed to NAD+ through an amidation reaction catalyzed by the NADSYN enzyme.
(B) The de novo biosynthesis of NAD+ from Trp starts with the conversion of Trp to N-formylkynurenine by either IDO or TDO. After four reaction steps, N-for-
mylkynurenine can be subsequently converted to the unstable ACMS, which can undergo nonenzymatic cyclization to quinolinic acid. The last step of the de novo
biosynthesis component is comprised of the QPRT-catalyzed formation of NAMN, using PRPP as a co-substrate, which is converted to NAD+ via the remaining
pathway described in (A).
(C) ACMS can also be diverted away fromNAD+ synthesis, by ACMSD, to formAMS and can then be oxidized via the glutarate pathway and TCA cycle to CO2 and
water, or nonenzymatically converted to picolinic acid.
(D) The synthesis of NAD+ from NAM or NR is more direct and relies on only two steps each. NAM is converted by the rate-limiting NAMPT to form NMN, using
PRPP as cosubstrate. NMN is also the product of phosphorylation of NR by the NR kinases (NRK1 and NRK2). The subsequent conversion of NMN to NAD+ is
catalyzed by the NMNAT enzymes. The blue boxes depict the three families of NAD+-consuming enzymes and some of the key processes to which they have
been linked. ACMS, a-amino-b-carboxymuconate-ε-semialdehyde; ACMSD, ACMS decarboxylase; AMS, a-amino-b-muconate-ε-semialdehyde; IDO, in-
doleamine 2,3-dioxygenase; NA, nicotinic acid; NAAD, NA adenine dinucleotide; NADSYN, NAD+ synthetase; NAMN, NAmononucleotide; NAMPT, nicotinamide
phosphoribosyltransferase; NAPRT, NA phosphoribosyltransferase; NMN, NAMmononucleotide; NMNAT, NMN adenylyltransferase; NR, nicotinamide riboside;
NRK, NR kinase; PRPP, phosphoribosyl pyrophosphate; QPRT, quinolinate phosphoribosyltransferase; TDO, tryptophan 2,3-dioxygenase; Trp, Tryptophan.
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found either in intestinal secretions (Gross and Henderson,
1983) or in the brush border (Baum et al., 1982). Next, NMN is
rapidly hydrolyzed to NR, which in turn is more slowly converted
into NAM (Gross andHenderson, 1983). NAMcan also be formed
directly by the cleavage of NAD+, obtaining ADP-ribose derivates
as a side product (Gross and Henderson, 1983). The intestinal
production of NAM from NAD+ or NR required the presence of32 Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc.intestinal cells, indicating that the enzymes for this process are
membrane-bound or intracellular (Baum et al., 1982; Gross and
Henderson, 1983). The direct perfusion with NAM, however,
did not give rise to any of these species, indicating that NAM is
the final degradation product and directly absorbed (Collins
and Chaykin, 1972; Gross and Henderson, 1983; Henderson
and Gross, 1979). In contrast, perfusion of the intestine with
NA revealed a substantial cellular accumulation of labeled
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which suggest the presence of active NAmetabolism in intestinal
cells (Collins and Chaykin, 1972; Henderson andGross, 1979). In
line with this, blood concentrations of NA are relatively low
(100 nM) yet, when pharmacologically primed (Jacobson
et al., 1995; Tunaru et al., 2003), can increase and be rapidly con-
verted to NAMby the liver (Collins and Chaykin, 1972). Strikingly,
NAM levels in fasted human plasma are also too low to support
NAD+ biosynthesis in cells (between 0.3 and 4 mM) (Hara et al.,
2011; Jacobson et al., 1995). All of these results suggest that
these NAD+ precursors are metabolized very quickly in mamma-
lian blood and tissues.
Lipid-Lowering Effect of Niacin
NA attracted clinical attention for its cholesterol lowering actions
(Altschul et al., 1955), and became the first drug used to treat
dyslipidemia. Gram dosages of NA reduce plasma triglyceride
and low-density lipoprotein (LDL) levels, while concomitantly
increasing high-densitiy lipoproteins (HDL). However, the clinical
use of NA has been limited by the fact that it induces cutaneous
flushing, which compromises compliance (Birjmohun et al.,
2005). This flushing does not derive from the ability of NA to drive
NAD+ synthesis, but rather from the activation of a G protein-
coupled receptor, GPR109A (Benyo´ et al., 2005). Given the low
presence of NA in blood, the activation of this receptor is unlikely
to be a native function of NA, but rather an effect from pharma-
cological dosing. It was also assumed that the beneficial effects
of NA on plasma lipids are mediated via a receptor rather than a
vitamin mechanism because of the high dose required (100-fold
higher than that required to prevent pellagra) and the failure of
NAM to provide similar benefits (Tunaru et al., 2003). Indeed,
some evidence supports that GPR109A is necessary for NA to
raise HDL cholesterol (Li et al., 2010; Tunaru et al., 2003). How-
ever, the absence of GRP109A expression in the liver (Soga
et al., 2003; Tunaru et al., 2003; Wise et al., 2003), a central
hub for HDL and LDLmetabolism, also questions whether the ef-
fects of NA on blood lipids derive from GPR109A activation.
Alternatively, strong evidence for the ability of NAD+ to enhance
the activity of sirtuins provides a mechanism of action that also
drives benefits on lipid homeostasis (Canto´ and Auwerx, 2012).
In addition, sirtuin activity is inhibited by NAM (Anderson et al.,
2003), which could explain why NAM failed to provide the bene-
fits of NA; however, in some situations, NAM treatments can
have beneficial effects as discussed in New Perspectives in
NAD+ Therapeutics (I): Metabolic Disease. The intricate relation-
ship between NAD+ and sirtuins will be discussed further in
NAD+-Consuming Enzymes (I): Sirtuins.
Introducing NAD+ as a Metabolic Regulator
The role of NAD+ as a coenzyme in most metabolic pathways
suggests that NAD+ limitations could affect metabolic efficiency.
Decreasing NAD+ levels could therefore prompt the develop-
ment of many of the ailments associated with aging. Indeed,
NAD+ levels can change during a number of physiological pro-
cesses. Diverse lines of research on worms, rodents, and human
cellular models indicate that declining NAD+ levels are a hallmark
for senescence (Braidy et al., 2011; Gomes et al., 2013; Khan
et al., 2014; Massudi et al., 2012; Mouchiroud et al., 2013; Ram-
sey et al., 2008; Yoshino et al., 2011). Along a similar line, a
reduction in muscle progenitor cell NAD+ content leads to a
SIRT1-mediatedmetabolic switch that induces premature differ-entiation and a loss of regenerative capacity, reflecting a pheno-
type typical of aging muscle (Ryall et al., 2015). The link between
metabolism and NAD+ is further solidified by observations that
tissue NAD+ levels decrease with high-fat diets (HFDs) (Bai
et al., 2011b; Canto´ et al., 2012; Kraus et al., 2014; Pirinen
et al., 2014; Yang et al., 2014; Yoshino et al., 2011). In contrast,
NAD+ increases in mammalian cells and tissues in response to
exercise (Canto´ et al., 2009, 2010; Costford et al., 2010) or calo-
rie restriction (CR) (Chen et al., 2008), both of which are interven-
tions associated with metabolic and age-related health benefits.
In line with this, supplementation with NAD+ precursors has
proven to enhance lifespan in budding yeast (Belenky et al.,
2007) and worms (Mouchiroud et al., 2013). Also, in mammals,
the enhancement of NAD+ levels has been linked with improved
mitochondrial function under stress (Cerutti et al., 2014; Khan
et al., 2014; Mouchiroud et al., 2013; Pirinen et al., 2014), leading
to protection against dietary (Bai et al., 2011b; Canto´ et al., 2012)
and age-related (Gomes et al., 2013; Yoshino et al., 2011) meta-
bolic complications. Finally, hepatic NAD+ levels dynamically
change in a circadian fashion (Asher et al., 2010; Nakahata
et al., 2009; Ramsey et al., 2009), weaving an intricate relation-
ship with nutritional states. Therefore, despite the classical
misconception that intracellular NAD+ levels rarely change
(Kaelin and McKnight, 2013), the evidence above unequivocally
demonstrates the ability of NAD+ to respond dynamically to
physiological stimuli. So, how do changes in NAD+ levels take
place innately?
NAD+ Synthesis and Salvage: New Ways to Boost NAD+
NAD+ Biosynthesis and the Discovery of New NAD+
Precursors
NAD+ availability is determined by the relative rates of NAD+
biosynthesis and degradation. Ergo, the enhancement of NAD+
biosynthesis could provide away to elevate NAD+ content. There
are several known NAD+ precursors. First, dietary Trp can serve
as an NAD+ precursor through an eight-step de novo pathway
(Bender, 1983), which has been described in detail elsewhere
(Houtkooper et al., 2010a); so, we will only focus on some of
its most interesting features (Figures 1A–1D). The first and
rate-limiting step in this path includes the conversion of Trp to
N-formylkynurenine by either indoleamine 2,3-dioxygenase
(IDO) or tryptophan 2,3-dioxygenase (TDO) (Figure 1B). These
enzymes are strongly overexpressed in diverse cancers, and
the subsequent synthesis of kynurenines may act as potential
second messengers in cancer immune tolerance (Stone and
Darlington, 2002), possibly through binding to the aryl hydrocar-
bon receptor (AHR) (Bessede et al., 2014). An interesting
branch point in the Trp catabolic pathway is the formation
of the unstable a-amino-b-carboxymuconate-ε-semialdehyde
(ACMS) (Bender, 1983). ACMS can be enzymatically converted
to a-amino-b-muconate-ε-semialdehyde (AMS) by ACMS de-
carboxylase (ACMSD), leading to complete oxidation via the
glutarate pathway and the tricarboxylic acid (TCA) cycle or to
the production of picolinic acid via a spontaneous reaction (Fig-
ures 1B and 1C) (Houtkooper et al., 2010a). Alternatively, ACMS
can undergo spontaneous cyclization forming quinolinic acid,
which subsequently serves as an NAD+ precursor (Bender,
1983). This latter nonenzymatic possibility seems to be only rele-
vant when the metabolism of ACMS is limited in the cell. ThisCell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 33
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NAD+ precursor in vivo, as it will only be diverted to NAD+ synthe-
sis when its supply exceeds the enzymatic capacity of ACMSD
(Ikeda et al., 1965). In humans, diets ranging from 34 mg to
86 mg of Trp provide the equivalent of 1 mg of niacin (reviewed
in Horwitt et al., 1981). Interestingly, the formation of NAD+
following Trp injections is further reduced in diabetic rats (Ikeda
et al., 1965). When ACMSD capacity is surpassed, Trp-derived
quinolinic acid is produced and used by quinolinate phosphori-
bosyltransferase (QPRT) to form NA mononucleotide (NAMN).
NAMN is then converted to NA adenine dinucleotide (NAAD),
using ATP, by the enzyme NMN adenylyltransferase (NMNAT)
(Figure 1A) (Houtkooper et al., 2010a). This is a key enzyme for
NAD+ synthesis in mammals, irrespective of the precursor
used, since it is also needed for NAD+ salvage. Three NMNAT
isoforms (NMNAT1–3) with different tissue and subcellular distri-
butions have been described in mammals (Lau et al., 2009).
NMNAT1 is a nuclear enzyme that is ubiquitously expressed,
with its highest levels in skeletal muscle, heart, kidney, liver,
and pancreas, yet it is almost undetectable in the brain (Ema-
nuelli et al., 2001). In contrast, NMNAT2 is mostly located in
the cytosol and Golgi apparatus (Berger et al., 2005; Yalowitz
et al., 2004). Finally, NMNAT3 is highly expressed in erythrocytes
with a moderate expression in skeletal muscle and heart
and has been identified in both cytosolic and mitochondrial
compartments, with cell-/tissue-specific subcellular localization
patterns (Berger et al., 2005; Felici et al., 2013; Hikosaka
et al., 2014; Zhang et al., 2003). The possible implications
of the subcellular localization of NMNAT enzymes will be dis-
cussed in Cell Compartmentalization of NAD+. The last step in
the primary biosynthesis of NAD+ includes the ATP-dependent
amidation of NAAD by NAD+ synthase (NADSYN) using gluta-
mine as a donor. NADSYN ismainly expressed in the small intes-
tine, liver, kidney, and testis, where this pathway may be more
relevant to NAD+ synthesis (Hara et al., 2003; Houtkooper
et al., 2010a).
NAD+ can also be synthesized from metabolite recycling or
the dietary uptake of other NAD+ precursors (Houtkooper
et al., 2010a). NA can lead to NAD+ through the shorter, three-
step Preiss-Handler pathway (Figure 1A). Here, NA is initially
metabolized by the NA phosphoribosyltransferase (NAPRT)
into NAMN, converging with the de novo pathway.
In mammals, NAM can also be an NAD+ precursor through its
metabolism into NAMmononucleotide (NMN) by the rate-limiting
enzyme nicotinamide phosphoribosyltransferase (NAMPT)
(Figure 1D) (Revollo et al., 2004; Rongvaux et al., 2002). NMN
can be then converted into NAD+ through a single additional
reaction catalyzed by the NMNAT enzymes. NAM is also the
product of NAD+ degradation by several enzyme families (see
The Enzymatic Use of NAD+). Consequently, NAMPT is key to
not only metabolizing circulating NAM, but also to recycling
intracellularly produced NAM via the NAD+ salvage pathway.
As a key enzyme, SNPs found in non-coding regions of human
NAMPT are correlated with glucose and lipid metabolism alter-
ations and type 2 diabetes, among other disease associations
(Zhang et al., 2011).
Lastly, NRmetabolism constitutes an additional path for NAD+
biosynthesis (Bieganowski and Brenner, 2004) (Figure 1D). NR is
transported into cells by nucleoside transporters (Nikiforov et al.,34 Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc.2011) and is then phosphorylated by the NR kinases 1 and 2
(NRKs) (Bieganowski and Brenner, 2004), generating NMN.
This phosphorylation step is a conserved feature in all eukary-
otes (Bieganowski and Brenner, 2004), underscoring its
evolutionary relevance. After the generation of NMN, NMNAT en-
zymes can then catalyze the formation of NAD+. While additional
ways for NR metabolism have been described in yeast (Belenky
et al., 2007), the phosphorylation by NRKs is still the only
pathway described in mammalian cells for the transformation
of NR into NAD+.
Whole-Body NAD+ Transport
Despite Trp being the canonical NAD+ precursor, its action may
be up to 60 times less efficient than NA (Institute ofMedicine (US)
Standing Committee on the Scientific Evaluation of Dietary
Reference Intakes and its Panel on Folate, Other B Vitamins,
and Choline, 1998), as Trp is also used for protein translation
and other biosynthetic purposes. Indeed, the use of Trp as an
NAD+ precursor would not be solely sufficient to support the
physiological NAD+ requirements in mammals (Henderson,
1997). NA, in contrast, can act as a potent NAD+ precursor,
primarily in liver and kidney where NAPRT demonstrates the
highest activity levels (Hara et al., 2007). However, mammalian
tissues are rarely exposed to NA, as its levels in blood are gener-
ally very low (Jacobson et al., 1995; Tunaru et al., 2003). Also, as
discussed in Food Sources and Bioavailability of NAD+, most
evidence suggests that NA might be quickly metabolized to
NAM in the gut and the liver (Collins and Chaykin, 1972). How-
ever, the low plasma concentration of NAM (Hara et al., 2011)
is 1,000-fold less than that required to increase NAD+ levels
in cultured cells (Hara et al., 2007; Revollo et al., 2004).
These findings underscore the importance of naturally occur-
ring NR as a possible alternative substrate for NAD+ biosynthesis
(Bieganowski and Brenner, 2004). Supporting this idea, NR
treatment enhances NAD+ levels in all mammalian cells tested
(Canto´ et al., 2012; Yang et al., 2007b). Interestingly, different
lines of evidence suggest that NR is the primary metabolite
transported into the cell and metabolized into NAD+, even
when cells are cultured in the presence NAD+ or NMN (Lu
et al., 2009) (Figure 2). Thus, by using specific inhibitors, it was
suggested that free NAD+ or NMN in the medium are metabo-
lized extracellularly to NR, which may be the final metabolite
transported to cells for NAD+ biosynthesis (Nikiforov et al.,
2011). Interestingly, milk extracts (whey vitamin fraction) rescue
the survival of yeast cells defective for QNS1, a necessary
enzyme for NA and NAM-triggered NAD+ biosynthesis in yeast
(Bieganowski and Brenner, 2004). This extract, however, failed
to rescue survival in NRK1-deficient yeast (Bieganowski and
Brenner, 2004). The presence of significant NR levels in blood
after oral intake is, however, not apparent, as classic reports
generally indicate that radiolabelled NR is transformed into
NAM at the brush border (Gross and Henderson, 1983). In this
sense, it is intriguing that mammalian cultured cells commonly
require almost millimolar NR concentrations in order to enhance
NAD+ biosynthesis (Canto´ et al., 2012; Yang et al., 2007b), which
is unlikely to be met in vivo. However, in some microorganisms,
such as Haemophilus influenza, only the transport of NR across
themembrane allows them to synthesize NAD+ and survive in the
host bloodstream, as they are unable to use NA, NAM, or the de
novo pathway for this purpose (Cynamon et al., 1988; Herbert
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Figure 2. Central Nodes for Cellular NAD+
Metabolism
In normal circumstances, most NAD+ or NMN in
blood is converted to NR, which enters the cell
through specific transporters and is metabolized
into NMN through NRK activity. Similarly, circu-
lating NAM can be metabolized to NMN ex-
tracellulary by the extracellular NAMPT or enter the
cell and be metabolized into NMN by the intracel-
lular NAMPT. Extracellular NA can also enter the
cell and be converted to NAD+ via a three-step
reaction that is reliant on NAPRT, NMNAT, and
NADSYN. NMN and, possibly, NAM are potentially
transported into the mitochondrial and nuclear
compartments. In those compartments, NMN can
lead toNAD+ synthesis via NMNAT activity. In each
subcellular compartment, NAD+ and NADH equi-
libriums will be determined by their unique redox
states. In the mitochondria, the ETC is a major
contributor to NADH oxidation into NAD+, coupling
this action to ATP synthesis. In addition, the mito-
chondria and the cytosol can exchange redox
equivalents through the malate/aspartate (M/A)
and glyceraldehyde 3-phosphate (G3P) shuttles. In
all compartments, the activity of NAD+-consuming
enzymes, such as sirtuins or PARPs, lead to NAM
production, which can be salvaged for NAD+ syn-
thesis via NAMPT activity. Dashed arrows indicate
pathways that need further validation.
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available in the blood. This is partially corroborated by a report
indicating that NMNmight be present in the bloodstream at con-
centrations around 50 mM (Revollo et al., 2007). The presence of
a circulating extracellular form of the NAMPT enzyme (eNAMPT),
to convert NAM to NMN, supports this possibility (Revollo et al.,
2007). Recent evidence indicates that eNAMPT activity in the
plasma is required to safeguard hypothalamic NAD+ levels
(Yoon et al., 2015). However, other labs have failed to detect
NMN in plasma (Hara et al., 2011). In addition, the marginal pres-
ence of ATP and 5-phosphoribosyl 1-pyrophosphate (PRPP) in
blood (Hara et al., 2011), both substrates for the reaction cata-
lyzed byNAMPT, would impede the generation of NMN in the cir-
culation. Furthermore, since NAMplasma levels are also low, it is
difficult to substantiate significant NMN synthesis in the blood-
stream (Hara et al., 2011).
All the above suggest that plasma levels of most NAD+ pre-
cursors are probably unable to systematically sustain high
NAD+ production rates. Consequently, it seems that mamma-
lian organisms largely rely on NAD+ salvage from intracellular
NAM in order to maintain NAD+ pools. In fact, NAM is an end
product of NAD+-consuming activities in the cell (i.e., sirtuins,
poly(ADP-ribose) polymerases and cyclic ADP-ribose hydro-
lases) (Houtkooper et al., 2010a). Accordingly, mice lacking
NAMPT are not viable (Revollo et al., 2007). This, however,
does not rule out a limited contribution of circulating NR,
NMN, NAM, or Trp to NAD+ biosynthesis under basal condi-
tions. However, further technical improvements will be needed,
especially for NR, NMN, and NAM determination, to precisely
evaluate the contribution of circulating precursors to NAD+
homeostasis.
Cell Compartmentalization of NAD+
In general, intracellular NAD+ levels are maintained between 0.2
and 0.5 mM, depending on the cell type or tissue. However,
NAD+ levels can change up to 2-fold in response to diversephysiological stimuli. For example, NAD+ levels increase in
response to energy stresses, such as glucose deprivation (Fulco
et al., 2008), fasting (Canto´ et al., 2010; Rodgers et al., 2005), CR
(Chen et al., 2008), and exercise (Canto´ et al., 2010; Costford
et al., 2010), and fluctuate in a circadian fashion (Nakahata
et al., 2009; Ramsey et al., 2009). So, where and how do these
changes take place in the cell?
The presence of NMNATs in the nucleus, cytosol, and mito-
chondria suggests that these compartments are fully capable
of salvaging NAD+ from NAM (Figure 2). NAD+-degrading en-
zymes, such as sirtuins, are also present in these compartments.
In addition, the presence of different forms of NMNATs in each
cellular compartment (e.g., NMNAT1 in the nucleus or NMNAT3
in the mitochondria/cytosol) suggests that NAD+ salvage is
tailored according to compartment-specific metabolic needs.
However, despite some evidence that NAMPT is localized to
the mitochondria (Yang et al., 2007a), there is still some debate
as to whether this is really the case (Pittelli et al., 2010). There-
fore, further experimental evidence is needed to confirm mito-
chondrial NAD+ salvage. Nonetheless, it is important to note
that NAD+ is not evenly distributed in the cell. Most reports indi-
cate that mitochondrial NAD+ content is R250 mM (Nakagawa
et al., 2009; Yang et al., 2007a), while according to indirect esti-
mations, nuclear NAD+ levels seem to be much lower, 70 mM
(Fjeld et al., 2003). To this effect, two-photon microscopy ap-
proaches have also been used to indirectly estimate NAD+
levels, confirming that NAD+ content in the nucleus is much
lower than in the cytosol (Zhang et al., 2009). In addition, the
different NAD+ pools can behave independently. As such, cells
treated with methylmethane sulfonate, a genotoxic agent, can
survive as long as mitochondrial NAD+ levels are maintained,
irrespective of NAD+ depletion in other compartments (Yang
et al., 2007a). Given that NAD+ or NADH cannot diffuse through
membranes (van Roermund et al., 1995), the maintenance of
NAD+ levels in each compartment is reliant on salvaging theCell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 35
Cell Metabolism
ReviewNAM produced by NAD+-consuming enzymes (Figure 2). Alter-
natively, it can be derived from the intermediates NMN or
NAMN, generated from NR metabolism or the Preiss-Handler
pathway, respectively. It was recently shown that exogenous
NAD+ can elevate mitochondrial NAD+ levels more than cyto-
plasmic levels, indicating that NAD+ precursors or intermediates
traverse the mitochondrial membrane (Pittelli et al., 2011).
Further, NR treatment was shown to enhance mitochondrial
NAD+ levels in cultured cells and in mouse liver (Canto´ et al.,
2012). However, the mitochondrial compartment lacks NRK ac-
tivity to initiate NR conversion into NAD+ (Nikiforov et al., 2011).
Hence, NR is likely converted to NMN in the cytosol, and NMN
may traverse the mitochondrial membrane to produce NAD+
via NMNATs (Figure 2) (Berger et al., 2005; Yang et al., 2007a).
This way, both NMN and NAMmight act as the main intracellular
forms for regulating NAD+ levels between compartments.
The compartmentalization of NAD+ synthesis may have even
more layers of complexity than once imagined. For example,
NMNAT1 is recruited to target gene promoters by either the
NAD+-consuming enzyme SIRT1 (Zhang et al., 2009) or PARP1
(Zhang et al., 2012), which suggests that NAD+ production is
regulated at a sub-compartmental level during transcriptional
regulation or DNA repair. These observations suggest that
SIRT1 and PARP1may compete for limiting amounts of localized
NMNAT1-produced NAD+. Thus, despite estimations indicating
that nuclear NAD+ levels are low, NAD+ maintenance is key for
survival, as testified by the fact thatNmnat1-KO is embryonically
lethal in mice (Conforti et al., 2011).
The Enzymatic Use of NAD+
NAD+ and Redox Reactions in Metabolism
While distinct, the cytosolic/nuclear and mitochondrial pools of
NAD+ are interconnected by an intricate set of cellular redox pro-
cesses. These NAD+ pools canmodulate the activity of compart-
ment-specific metabolic pathways such as glycolysis in the
cytoplasm and the TCA cycle/oxidative phosphorylation in the
mitochondria.
In the cytoplasm, the conversion of glucose to pyruvate
by glycolysis requires two NAD+ molecules per molecule of
glucose. Following the conversion of glucose to two molecules
of glyceraldehyde-3-phosphate (G3P), glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) reduces NAD+ to NADH to
transform G3P into 1-3-biphosphoglycerate. Glycolysis will
therefore net two NADH and two pyruvate molecules that can
then be transported into to the mitochondrial matrix. Since the
outer mitochondrial membrane is very porous, NADH is free to
enter the intermembrane space. However, it is the reducing
equivalent of NADH that is transported into the mitochondria,
via either the malate-aspartate shuttle or the glycerol-3-phos-
phate shuttle of the inner mitochondrial membrane, rather than
NADH itself (Figure 2) (McKenna et al., 2006). As discussed in
Cell Compartmentalization of NAD+, cytoplasmic NAD+ levels
cannot alter mitochondrial NAD+/NADH ratios directly since
NAD+ is not permeable to the mitochondrial membrane (Barile
et al., 1996). Therefore, changes in the cytoplasmic NAD+ pool
do not acutely alter mitochondrial NAD+ levels (Pittelli et al.,
2010; Yang et al., 2007a).
In the mitochondrion, the TCA cycle reduces NAD+ molecules
to produce multiple NADH molecules. Mitochondrial NADH,36 Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc.gained from glycolysis or the TCA cycle, are oxidized by
Complex I (NADH:ubiquinone oxidoreductase) of the ETC. The
subsequent two electrons gained by Complex I are relayed
along ubiquinone (Coenzyme Q10), complex III (coenzyme
Q-cytochrome c oxidoreductase), cytochrome c, and Complex
IV (cytochrome c oxidase). In parallel to the oxidation of NADH
to NAD+ by the ETC, the substrate succinate from the mitochon-
drial TCA cycle provides additional electrons to ubiquinone in
parallel with Complex I. Ultimately, the flow of electrons, gener-
ated from NADH and succinate, along the ETC is coupled to the
pumping of protons from the mitochondrial matrix to the inter-
membrane space via Complex I, III, and IV, creating a proton
gradient. The proton gradient then provides the chemiosmotic
gradient to couple the flux of protons back into the matrix via
F0F1-ATP synthase with oxidative phosphorylation of ADP to
ATP. Overall, the ETC reduces O2 to water and NADH to NAD
+
for the purpose of generating ATP. As a result, mitochondrial
NAD+ levels are 2-fold greater than the rest of the cell, as
measured in mouse skeletal muscle (Pirinen et al., 2014), and
4-fold greater in mouse cardiac myocytes (Alano et al., 2007).
Since NAD+ levels within the cell can be limiting (Bai et al.,
2011b; Pirinen et al., 2014; Pittelli et al., 2011), both glycolysis
in the cytoplasm and the TCA cycle in themitochondria can influ-
ence metabolic homeostasis by altering cytosolic/nuclear NAD+
and NADH levels. In addition, following DNA damage, NAD+
levels can drop low enough that glycolysis and substrate flux
to the mitochondria is blocked, leading to cell death, despite
having an excess of available glucose (Alano et al., 2010; Bena-
vente et al., 2009; Ying et al., 2005; Zhang et al., 2014). This
finding highlights the need to understand the mechanisms inter-
connecting subcellular NAD+ pools, as their homeostasis and
interactions are essential for the preservation of cell viability
and ATP levels.
NAD+-Consuming Enzymes (I): Sirtuins
In mammals, there are seven sirtuin enzymes (SIRT1–SIRT7)
based on the presence of a characteristic and evolutionarily
conserved catalytic site, comprised of 275 amino acids (Haigis
and Sinclair, 2010; Hall et al., 2013; Houtkooper et al., 2010a).
Three sirtuins are located in the mitochondria (SIRT3–SIRT5),
while SIRT1, SIRT6 and SIRT7 are predominantly located in
the nucleus, and SIRT2 is found in the cytoplasm (Michishita
et al., 2005; Verdin et al., 2010). However, some sirtuins, such
as SIRT1, have been shown to shuttle in and out of the nucleus
(Tanno et al., 2007).
Sirtuins use NAD+ as a cosubstrate to remove acetyl moieties
from lysines on histones and proteins, releasing NAM and
O-acetyl-ADP-ribose (Houtkooper et al., 2010a). The consump-
tion of NAD+ during deacetylation is what separates sirtuins, as
type III lysine deactylases (KDACs), from type I, II, and IV KDACs.
SIRT1, SIRT2, and SIRT3 have strong deacetylase activity (Imai
et al., 2000; North et al., 2003; Schwer et al., 2002; Vaziri et al.,
2001), while SIRT4, SIRT5, and SIRT6 are weak in comparison.
However, deacetylation is not the singular function of all sirtuins,
as SIRT4 can act as a lipoamidase (Mathias et al., 2014) and,
along with SIRT6, as an NAD+-dependent mono-ADP-ribosyl-
transferase (Haigis et al., 2006; Liszt et al., 2005). SIRT6 can
also efficiently remove long-chain fatty acyl groups from lysine
residues (Jiang et al., 2013), while SIRT5 has strong desucciny-
lase, demalonylase, and deglutarylase enzymatic activities
AB
Figure 3. The Reciprocal Relationship
between SIRT1 and PARPs during NAD+
Homeostasis and Metabolic Signaling in the
Cell
(A) NAD+ is an essential coenzyme for sirtuin,
PARP, and CD38 activity, all of which metabolize
NAD+ into NAM. Glycolysis and the TCA cycle also
consume available NAD+ for the production of
NADH, providing reducing equivalents for either
lactate dehydrogenase (LDH) or the ETC. Red font
indicates environmental or physiological stimuli
that activate sirtuins by increasing NAD+, while
blue font indicates a reduction in NAD+, thereby
diminishing sirtuin activity. NAM can be shunted
away from NAD+ production following methylation
by NNMT, a pathway activated by a HFD or with
long-term or high doses of NAM, which can favor
the development of a fatty liver, due to reductions
in available methyl groups. In contrast, NNMT
depletion by NNMT-antisense oligonucleotides in
animals or mNAM supplementation in cells re-
duces NAM methylation. With a HFD, NAD+ can
be reduced by elevating energy availability and
NADH production, while exercise, fasting, and CR
reverses this process providing more NAD+ for
sirtuin activation and protein deacetylation. NR
supplementation or intraperitoneal NMN increases
NAD+ availability via the NAD+ salvage pathway
in mice. Ultimately, SIRT1 induces mitochondrial
biogenesis, energy expenditure, antioxidant de-
fenses, and lifespan extension by a mechanism
that involves the mitochondrial unfolded protein
response (UPRmt). PARPs consume NAD+, reducing SIRT1 activity, by increasing PARylation of DNA and proteins during aging, cancer, neurodegeneration,
and mitochondrial diseases.
(B) SIRT1 negatively regulates PARP1 through the inhibition of transcription and possibly through deacetylation. Reciprocally, PARP1 inhibits SIRT1 by limiting
NAD+ levels, while PARP2 directly inhibits SIRT1 transcription. Interestingly, PARP1 is required for the transcriptional co-activation of NF-kB, while SIRT1 inhibits
NF-kB activity through the deacetylation of RelA/p65. In addition, PARP1 and SIRT1 oppositely regulate p53 nuclear accumulation and activation following
cytotoxic stress. Since the Km of PARP1 for NAD
+ is lower than that of SIRT1, as NAD+ levels drop following cell stress or senescence, SIRT1 becomes less
effective at regulating PARP1, and inhibiting inflammation or cell death through the inactivation of NF-kB and p53. Dashed arrows indicate pathways that need
further validation.
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dependent deacetylase with few known substrates, including
p53 in vitro (Vakhrusheva et al., 2008), PAF53 in HeLa cells
(Chen et al., 2013), and GABPb1 in vivo (Ryu et al., 2014). Recent
evidence indicates that long-chain deacylation is a general
feature of all mammalian sirtuins (Feldman et al., 2013). For
example, SIRT1, SIRT2, and SIRT3 can also act as effective de-
crotonylases (Bao et al., 2014; Feldman et al., 2013). The general
deacylase activity of sirtuins, however, can differ in their prefer-
ential activity toward certain acyl chain lengths (Feldman et al.,
2013).
Physiological Roles of Sirtuins. Generally, most sirtuins are
activated during times of energy deficit and reduced carbohy-
drate energy sources, triggering cellular adaptations that
improve metabolic efficiency (Figure 3A). For example, SIRT1
activity increases during exercise (Canto´ et al., 2009), CR
(Chen et al., 2008), fasting (Canto´ et al., 2010; Rodgers et al.,
2005), or low glucose availability (Fulco et al., 2008), all of which
correlate with higher NAD+ levels. Due to space limitations, we
will only briefly summarize the roles of sirtuins. For further infor-
mation, we refer the reader to recent specialized reviews (Bou-
tant and Canto, 2014; Chang and Guarente, 2013; Houtkooper
et al., 2012).
Different nuclear sirtuin orthologs have been shown to influ-
ence lifespan in yeast, worms, flies, and mice (Bauer et al.,
2009; Boily et al., 2008; Kaeberlein et al., 1999; Kanfi et al.,2012; Rogina and Helfand, 2004; Tissenbaum and Guarente,
2001). Accordingly, the deacetylation of transcription factors,
cofactors, and histones by SIRT1 was shown to be important
to enhance mitochondrial metabolism (Boily et al., 2008; Canto´
et al., 2009, 2010; Feige et al., 2008; Menzies et al., 2013; Price
et al., 2012; Rodgers et al., 2005). Further evidence indicates that
SIRT1 is key to linking nutrients to circadian rhythm (Asher et al.,
2008; Chang and Guarente, 2013; Nakahata et al., 2008). The
tight link between sirtuins and metabolism was reinforced by
findings indicating that a moderate SIRT1 overexpression in
mice could prevent metabolic and age-related complications,
including insulin resistance, obesity, and hepatic steatosis
(Banks et al., 2008; Herranz et al., 2010; Pfluger et al., 2008). In
addition, pharmacological SIRT1 activation protects against
lifespan reductions prompted by HFDs (Baur et al., 2006;
Minor et al., 2011). Similarly, SIRT6 overexpression has been
shown to increase mouse lifespan (Kanfi et al., 2012). Oppo-
sitely, loss-of-function models for SIRT1, SIRT3, and SIRT7
have been linked to a higher susceptibility to metabolic and
age-related disease or reduced maximal lifespan (Boutant and
Canto, 2014; Hirschey et al., 2011; Ryu et al., 2014; Vakhrusheva
et al., 2008), while the absence of SIRT6 causes severe hypogly-
cemia, leading to mortality within the first month of life (Mosto-
slavsky et al., 2006; Zhong et al., 2010). Sirt2- and Sirt5-deficient
mice, however, do not display an overt metabolic phenotype in
the basal state (Beirowski et al., 2011; Bobrowska et al., 2012;Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 37
Table 1. NAD+-Consuming Enzymes
Enzyme Km Value (mM) References
SIRT1 94–96 Gerhart-Hines et al., 2011;
Pacholec et al., 2010
SIRT2 83 Borra et al., 2004
SIRT3 880 Hirschey et al., 2011
SIRT4 35 Laurent et al., 2013
SIRT5 980 Fischer et al., 2012
SIRT6 26 Pan et al., 2011
SIRT7 Unknown
PARP1 50–97 Ame´ et al., 1999;
Jiang et al., 2010;
Mendoza-Alvarez and
Alvarez-Gonzalez, 1993
PARP2; PARP4 (VPARP) 130; unknown Ame´ et al., 1999
Tankyrase 1 (PARP5a);
Tankyrase 2 (PARP5b)
1,125–1,500;
unknown
Jiang et al., 2010;
Rippmann et al., 2002
CD38 15–25 Cakir-Kiefer et al., 2001;
Fulco et al., 2008;
Sauve et al., 1998
Only poly-ADP-ribosylating PARPs were included in this table.
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ReviewYu et al., 2013), while Sirt4 deficiency, in contrast to most sir-
tuins, enhances oxidative metabolism (Laurent et al., 2013).
Sirtuins as NAD+ Sensors. Their ability to use NAD+ as a sub-
strate led to speculation that sirtuins could act as metabolic
sensors. The activity of sirtuins for a given intracellular NAD+
level is defined by the Michaelis constant, Km, for the reaction.
This constant describes the NAD+ concentration when the reac-
tion rate is half of the maximum during NAD+ excess. The esti-
mated total intracellular content of NAD+ in mammals ranges
from 200 to 500 mM (Bai et al., 2011b; Hong et al., 2014;
Houtkooper et al., 2010a; Schmidt et al., 2004). The Km of
SIRT1 for NAD+ has been reported to be in the range of 94–
96 mM in mammals (Table 1) (Gerhart-Hines et al., 2011; Pacho-
lec et al., 2010). The Km for NAD
+, however, can differ very signif-
icantly between sirtuins. For example, the Km for NAD
+ of SIRT2,
SIRT3, SIRT4, SIRT5, and SIRT6 are reported as 83 mM (Borra
et al., 2004), 880 mM (Hirschey et al., 2011), 35 mM (Laurent
et al., 2013), 980 mM (Fischer et al., 2012), and 26 mM
(Pan et al., 2011), respectively. The affinity of SIRT7 for NAD+
has not been reported to our knowledge. The above numbers
help to classify sirtuins into two different categories. First, there
are sirtuins, such as SIRT2, SIRT4, and SIRT6, whose activity
is unlikely to be rate-limited by NAD+, as NAD+ availability is
considerably higher than their Km values. In contrast, there are
other sirtuins, such as SIRT1, SIRT3, and SIRT5, whose Km for
NAD+ falls within the range for physiological changes in NAD+.
In this respect, it is important to note that SIRT1 is a nuclear
enzyme, and NAD+ concentrations in the nucleus are below
100 mM, while NAD+ levels in the mitochondria can reach milli-
molar values, suggesting that NAD+ could limit SIRT3 and
SIRT5 based on their Km values.
The above observations indicate that few sirtuins (i.e., SIRT1,
SIRT3, and SIRT5) fulfill the key criteria to be considered NAD+
sensors. However, sirtuins are not exclusively regulated by
NAD+. For example, NAM, the end product of the sirtuin reaction,38 Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc.acts as a potent and general sirtuin deacetylase inhibitor. NAM
was in fact shown to inhibit Sir2p, the yeast SIRT1 ortholog in
a non-competitive manner with NAD+, with an IC50 < 50 mM (An-
derson et al., 2003; Bitterman et al., 2002; Borra et al., 2004).
Thus, sirtuin activity can potentially be differentially regulated
by the cellular concentrations of both NAD+ and NAM.
NADH has also been proposed to act as an inhibitor of SIRT1
through competitive binding of the NAD+ pocket (Lin et al., 2004).
Yet, the inhibition by NADH only occurs in the millimolar range,
considerably above physiological NADH levels (Schmidt et al.,
2004; Smith et al., 2009; Zhang et al., 2002). For example, intra-
cellular concentrations of NADH in muscle cells range from 50 to
100 mM (Canto´ et al., 2012; Hong et al., 2014). Thus, based on the
above findings, the intracellular NAD+/NAM ratio may be a better
predictor of sirtuin activity compared to the popularly used
NAD+/NADH ratio.
NAD+-Consuming Enzymes (II): Poly(ADP-ribose)
Polymerases
Poly(ADP-ribose) polymerases (PARPs) have been the center of
intense focus due to their active role in DNA repair, inflammation,
and cell death, but they have now also been shown to influence
circadian rhythm, neuronal function, endoplasmic reticulum
stress, and metabolism, among other cellular pathways (re-
viewed in Canto´ et al., 2013; Gibson and Kraus, 2012; Kraus
and Hottiger, 2013). There are 17 different genes encoding
PARP-related proteins (Gibson and Kraus, 2012), but most
research has so far focused on PARP1 and PARP2, which
account for the vast majority of PARP activity in the cell (Canto´
et al., 2013). In general, PARP1 and PARP2 can be activated
by DNA strand breaks endowing themwith a role in the response
toDNAdamage (Ame´ et al., 1999; Benjamin andGill, 1980; Grad-
wohl et al., 1990). However, PARPs can also be activated by
interactions with the phosphorylated form of extra signal-regu-
lated kinases (ERKs) to amplify ERK-mediated histone acetyla-
tion events (Cohen-Armon et al., 2007). Furthermore, PARPs
are also activated by HSP70 during heat shock stress to alter
nucleosome structure and by Trp tRNA synthetase (TrpRS) (Pe-
tesch and Lis, 2012; Sajish and Schimmel, 2015). Active PARP
catalyzes the transfer of ADP-ribose subunits from NAD+ to pro-
tein acceptors, including different nuclear protein substrates,
and even itself (a process called auto-poly-ADP-ribosylation),
thus forming PAR chains (Kameshita et al., 1984). Classically,
PARPs have been shown to play dual roles in the cell that can
either result in the induction of cell death or DNA repair.
PARP1, for instance, was shown to modify the effectiveness of
the p53-mediated DNA damage response for different types of
cytotoxic stress (Valenzuela et al., 2002). As a result, PARP inhi-
bition can be an effective treatment for cancer (Bryant et al.,
2005; Farmer et al., 2005; Fong et al., 2009), leading to the devel-
opment of several potent PARP inhibitors as chemotherapeutic
agents. From a purely metabolic angle, PARP1 activation has
also been linked to a rapid reduction in the glycolytic rate. While
this phenomenon has been classically linked to a reduction in
NAD+ availability, recent evidence indicates that PARP1 might
also directly PARylate hexokinase, leading to a reduction in
hexokinase activity and the cellular glycolytic rate (Andrabi
et al., 2014; Fouquerel et al., 2014). Indeed, the possible direct
impact of PARP activities on metabolic enzymes will be a fasci-
nating area of research for years to come.
Cell Metabolism
ReviewThe Competition between PARPs and Sirtuins for NAD+ as a
Metabolic Determinant. Upon DNA damage, PARP enzymes
utilize NAD+ to generate PAR polymers, yielding NAM as a reac-
tion product. Excessive DNA damage dramatically reduces
NAD+ levels (Berger, 1985), even down to 20%–30% of their
normal levels (Houtkooper et al., 2010a). In fact, the enzymatic
properties of PARP1 indicate that it is an avid NAD+ consumer,
with NAD+ increasing up to 2-fold in Parp1-KO mouse tissues
(Bai and Canto´, 2012). This, in turn, limits NAD+ availability for
other nuclear enzymes such as SIRT1 (Figure 3A) (Bai et al.,
2011b; Pillai et al., 2005; Qin et al., 2006; Rajamohan et al.,
2009). In fact, the Km of PARP1 is in the50–59 mM range, unlike
like that of PARP2 (Km 130 mM), dictating that NAD
+ is rarely rate-
limiting for PARP1 activity (Table 1) (Ame´ et al., 1999; Mendoza-
Alvarez and Alvarez-Gonzalez, 1993). The lower affinity for, and
consumption rate of, NAD+ by PARP2 is in agreement with the
lack of change in NAD+ levels when PARP2 is knocked down
in cultured cells (Bai et al., 2011a). Interestingly, however,
Parp2 deficiency increased SIRT1 expression as a consequence
of a direct negative regulatory effect on the SIRT1 promoter
(Figure 3B) (Bai et al., 2011a). This further illustrates how PARP
activity leads to SIRT1 inactivation, either by limiting NAD+ levels,
in the case of PARP1 (Bai et al., 2011b), or by acting as a tran-
scriptional repressor, in the case of PARP2 (Bai et al., 2011a).
The complexity of this pathway was heightened when SIRT1
was shown to directly inhibit PARP1 via its deacetylation
(Figure 3B). Specifically, increased PAR activity was observed
in Sirt1-KO cells treated with H2O2 (Kolthur-Seetharam et al.,
2006), while the ability of SIRT1 to deacetylate PARP1 was
confirmed by immunoprecipitation experiments (Rajamohan
et al., 2009). Furthermore, SIRT1 also negatively regulates
PARP1 transcription (Rajamohan et al., 2009). Illustrating the
opposing roles of both enzymes, PARP1 is required for the tran-
scriptional co-activation of NF-kB (Hassa et al., 2003), while
SIRT1 inhibits NF-kB activity through the deacetylation of
RelA/p65 (Yeung et al., 2004). Furthermore, PARP1 and SIRT1
have opposing effects on p53 nuclear accumulation and activa-
tion following cytotoxic stress (Figure 3B) (Langley et al., 2002;
Luo et al., 2001; Valenzuela et al., 2002; Vaziri et al., 2001). Since
the Km of SIRT1 for NAD
+ is higher than that of PARP1, NAD+
levels can become so low following cell stress or senescence
that SIRT1 no longer has the activity to keep PARP1 in check.
This is supported by the fact that NAD+-repletion by expression
of NAMPT can protect against PARP1 overexpression in a
SIRT1-mediated manner (Pillai et al., 2005). Thus, it is likely
that diverse cellular fates and metabolic decisions are closely
regulated by the balance of the reciprocal regulation of SIRT1
and PARP1 activities, under the guidance of NAD+ levels
(Figure 3B).
Recent work has further strengthened the hypothesis that
PARP1 and SIRT1 have counterbalancing roles in metabolism
and aging. For instance, PARP1 activity is enhanced with aging
(Braidy et al., 2011; Mouchiroud et al., 2013) and high caloric
intake (Bai et al., 2011b) yet reduced upon nutrient scarcity
(Bai et al., 2011b). Parp1 deletion in C57Bl/6 mice confers pro-
tection against diet-induced obesity (Bai et al., 2011b). Strikingly,
Parp1-deficiency on a 129/SvImJ background has been re-
ported to exacerbate HFD-induced obesity (Devalaraja-Nara-
shimha and Padanilam, 2010). In addition, some studies haveshown that Parp1 deficiency can limit adipocyte function and
size, leading to higher hepatic lipid accumulation (Erener et al.,
2012). Despite these discrepancies, pharmacological PARP inhi-
bition has consistently rendered protection against diet-induced
obesity (Lehmann et al., 2015; Pirinen et al., 2014), possibly
through an upregulation of SIRT1-dependent mitochondrial
biogenesis and energy expenditure via the mitochondrial
unfolded protein response (UPRmt; see New Perspectives in
NAD+ Therapeutics (IV): Aging) (Pirinen et al., 2014). In addition,
when the PARP1 worm homolog, pme-1, was knocked down in
C. elegans, worms lived longer and maintained a more youthful
phenotype at late adult stages (Mouchiroud et al., 2013). This
was correlated to a marked increase in NAD+ availability, Sir2.1
activity, and mitochondrial function that were linked to the acti-
vation of the UPRmt (Mouchiroud et al., 2013). Altogether, most
studies certify that a reduction in PARP activity is beneficial
against some aspects of metabolic disease.
Importantly, PARP inhibition might lead to higher NAD+ avail-
ability in a compartment-specific fashion. In line with the pre-
dominant localization of PARP1 to the nucleus, reductions
in PARP1 activity/expression markedly increases nucleo/cyto-
plasmic NAD+ levels and SIRT1 activity, yet it does not alter mito-
chondrial NAD+ or SIRT3 activity (Bai et al., 2011b; Pirinen et al.,
2014). However, this notion will need to be consolidated when
further technical developments allow us to better directly mea-
sure NAD+ levels in a compartment-specific fashion, most
notably in the nucleus.
To strengthen the hypothesis that PARPs can consume
NAD+ to the point of impeding metabolism, the AHR target
gene, TiPARP (TCDD-inducible poly(ADP-ribose) polymerase
or PARP7), was shown to increase PARylation of proteins,
reducing NAD+ levels and SIRT1-mediated PGC-1a deacetyla-
tion in liver tissue (Diani-Moore et al., 2010). Furthermore,
tankyrase 2 (PARP5b)-KO mice also have reduced fat pad and
body weights, although no connection has yet been made to
improvements in tissue NAD+ levels (Chiang et al., 2006). Alto-
gether, these results suggest that ADP-ribosylation by several
PARP family members can lead to metabolic dysfunction, sug-
gesting that PARP inhibitors may have beneficial effects in this
context.
NAD+-Consuming Enzymes (III): Cyclic ADP-Ribose
Synthases
Cyclic ADP-ribose (cADPR), a secondary messenger implicated
in Ca2+ signaling, cell cycle control and insulin signaling (Mala-
vasi et al., 2008), is produced from NAD+ by cADPR synthases.
The family of cADP-ribose synthases, including CD38 and its
homolog CD157, were initially described as plasma membrane
antigens on thymocytes and T lymphocytes. However, these
ectoenzymes have also been found in non-lymphoid tissues,
including muscle, liver, and brain (Aksoy et al., 2006b; Quarona
et al., 2013). In addition, recent topological studies have
described the enzymatic activity of this transmembrane protein
as both extra- and intra-cellular (Jackson and Bell, 1990; Lee,
2012; Zhao et al., 2012).
Mice deficient in Cd38 show significantly elevated levels of
NAD+ (10- to 30-fold) in tissues such as liver, muscle, brain,
and heart, with corresponding SIRT1 activation, confirming
the role of CD38 as a major NAD+ consumer (Figure 3A)
(Aksoy et al., 2006b; Barbosa et al., 2007). Conversely, cellsCell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 39
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the expression of proteins related to energy metabolism and
antioxidant defense, as measured by quantitative proteomic
analysis (Hu et al., 2014). Similar to Parp1-deficient mice,
Cd38-KO animals were protected from diet-induced obesity,
liver steatosis, and glucose intolerance due to enhanced energy
expenditure (Barbosa et al., 2007). In fact, the influence of Cd38
defiency on metabolism is so dramatic that, despite having
lower physical activity compared to WT animals, they still
expendmore total energy. One potential issue is that CD38-inde-
pendent cADPR synthase and NAD+-glycohydrolase activity re-
mained present in the developing brain of Cd38-KO mice
(Ceni et al., 2003). Similarly, studies in heart (Kannt et al., 2012;
Xie et al., 2005), skeletal muscle (Bacher et al., 2004), and kidney
(Nam et al., 2006) also demonstrated that cADPR synthesis
occurs independently of CD38 and CD157, suggesting the
existence of other cADPR synthase family member(s). In further
support of the existence of additional cADPR synthases, a
small-molecule compound screen discovered two potent
inhibitors, SAN2589 and SAN4825, that do not inhibit CD38
yet blunt cardiac cADPR synthase activity (Kannt et al., 2012).
Despite observations that CD38 inhibition appears to enhance
NAD+ levels, further work should clarify its cellular location and
specific roles in various tissues to make it a viable therapeutic
target.
Recent Advances in NAD+-Related Therapeutics
Although NA is effective to treat dyslipidemia (Altschul et al.,
1955), due to its undesirable effects, niacin derivatives including
acipimox and prolonged release forms, such as niaspan and en-
duracin, have largely replaced NA use in the clinical manage-
ment of hyperlipidemia. The core of the hypothesis explaining
the effectiveness of niacin rested in part on the activation of
GPR109A in adipocytes, which apparently mediated the tran-
sient reduction of plasma free fatty acid (FFA) levels (Tunaru
et al., 2003; Zhang et al., 2005). Yet, more recently, using both
a mouse line deficient in Gpr109 and clinical trials with two
GPR109 agonists, it became clear that GPR109 did not mediate
niacin’s lipid efficacy, thus questioning the GPR109-mediated
FFA hypothesis (Lauring et al., 2012). This, in turn, gave strength
to the possibility that the effects of niacin relied on the ability of
NA or NAM to elevate NAD+ levels and activate sirtuins (Canto´
and Auwerx, 2012). Beyond niacin, other NAD+ precursors,
such as NMN and NR, are being considered as alternatives to
niacin, since they do not activate GPR109A receptors, yet still
activate SIRT1 in mice (Canto´ et al., 2012). Similarly, the inhibi-
tion of PARP or CD38 activities has also proven to enhance
NAD+ levels and sirtuin action (Figure 3A). Further disqualifying
a GPR109-mediated effect and in support an NAD+-mediated
metabolic response, in human type 2 diabetes patients, acipi-
mox increases muscle mitochondrial function, which is accom-
panied by a mitonuclear protein imbalance and the induction
of the UPRmt (see New Perspectives in NAD+ Therapeutics (I):
Metabolic Disease and New Perspectives in NAD+ Therapeutics
(IV): Aging), hallmarks of SIRT1, in lieu of GPR109, activation (van
de Weijer et al., 2014). In the next section, we will hence discuss
the therapeutic targets, the prospective clinical indications, and
the potential limitations for NAD+-boosting compounds that
activate sirtuins.40 Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc.New Perspectives in NAD+ Therapeutics (I): Metabolic
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Introducing New NAD+ Precursors: NR and NMN. NR was
recently demonstrated to have a surprisingly robust effect on
systemic metabolism. First, dietary supplementation with NR
protected against diet-induced obesity (Canto´ et al., 2012). NR
treatment increased both intracellular and mitochondrial liver
NAD+ levels, concomitant to an enhancement of SIRT1 as well
as SIRT3 activities (Canto´ et al., 2012). As a result, there was a
SIRT1-dependent increase in FOXO1 deacetylation, along with
elevations in SOD2 expression, a FOXO1 target gene. Further-
more, in the mitochondrial compartment, NR led to the deacety-
lation of the well-established SIRT3 targets SOD2 and NDUFA9.
In line with the activation of SIRT1 and SIRT3 targets, mitochon-
drial content was higher in skeletal muscle and brown adipose
tissue of NR-treated high-fat-fed animals, which increased the
use of lipids as energy substrates, boosted energy expenditure,
and improved insulin sensitivity (Canto´ et al., 2012). In alignment,
impaired glucose tolerance and glucose-stimulated insulin
secretion, induced by NAD+ shortages in NAMPT-deficient
heterozygous animals, could be corrected by the administration
of NMN (Revollo et al., 2007). Similarly, intraperitoneally admin-
istered NMN ameliorates glucose homeostasis in age- and
diet-related insulin-resistant states (Ramsey et al., 2008; Yosh-
ino et al., 2011). Importantly, NMN reversed the loss of NAD+
levels observed in both circumstances. As with NR, NMN also
safeguarded mitochondrial function in mice and improved
age-related mitochondrial dysfunction (Gomes et al., 2013).
Knockdown of the nuclear-localized NMNAT1 attenuated
the effect of NMN, consistent with the effect of NMN being
driven by increases in NAD+ levels (Gomes et al., 2013). Further-
more, as NMNAT1 is located in the nucleus, the nuclear NAD+
pool may play a more dominant role for the induction of mito-
chondrial-encoded OXPHOS transcripts, potentially through
alterations in SIRT1-directed HIF1a destabilization, leading to
c-Myc activation of the nuclear-encoded mitochondrial factor
TFAM (Gomes et al., 2013). Although these findings support
the use of NR or NMN as a strategy for healthy aging, their effi-
cacy in humans still needs testing. In fact, the dosages used
for NR and NMN in mice, 400–500 mg/(kg,day), are high and
potentially suboptimal for human application. Unlike NR, the
use of NMN in mice has relied on intraperitoneal delivery, which
could further complicate clinical use. Thus, the dosages, routes
of administration, and efficacy of NAD+ boosters need to be opti-
mized for human use.
Rejuvenating Old NAD+ Precursors: The Complexities around
NAM. NAM, was first associated with diabetes when it was
shown to protect against streptozotocin (STZ)-induced diabetes
(Schein et al., 1967), which is accompanied by a robust reduction
of NAD+ levels in pancreatic islet cells. NAM, but not NA, can
recover this drop in NAD+ levels (Ho and Hashim, 1972). Later,
it was demonstrated that the NAD+ reduction induced by STZ
was due to increased DNA damage, stimulating PARP1 activity
(Yamamoto et al., 1981).
Unlike other NAD+ precursors, NAM has the capacity to exert
end product inhibition on SIRT1 deacetylase activity. However,
long-term NAM treatment increases NAD+ levels via the NAD+
salvage pathway, which likely tips the balance of the NAD+/
NAM ratio such that SIRT1 is activated. Despite NAM being
Figure 4. Energy Stress, NAD+-Dependent UPRmt Signaling, and
Mitochondrial Health
The aging process and associated metabolic diseases, including obesity and
mitochondrial diseases, can be improved in mice and C. elegans using NAD+
boosters or PARP/CD38 inhibitors (PARPi/CD38i) inmuch the sameway as has
been demonstrated by CR. Part of the metabolic decline during aging is due to
a PARP-directed reduction in NAD+ levels, attenuating SIRT1 and FOXO3A
activities and leading to the activation of HIF1a and an increased reliance on
glycolysis. Recently, a mechanism has been proposed for these NAD+-medi-
ated improvements that include the induction of the UPRmt, which is triggered
by SIRT1- and SIRT3-induced mitochondrial biogenesis, creating an imbal-
ance in mitochondrial- versus nuclear-encoded mitochondrial proteins. This
mitonuclear imbalance activates the UPRmt, a retrograde signal that induces
a mitohormetic and adaptive nuclear response, ultimately repairing and
improving mitochondrial function. These mitohormetic signals can attenuate
the impact of aging, mitochondrial diseases, or a HFD on metabolism.
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clinical trials failed to confirm this hypothesis (Cabrera-Rode
et al., 2006; Gale et al., 2004). More recently, OLETF rats,
a rodent model of obesity and type 2 diabetes, exhibited
profound metabolic improvements following NAM treatment
(100 mg/kg for 4 weeks). This treatment induced liver NAD+
levels, which were complimented by enhanced glucose control
(Yang et al., 2014). However, some reports indicate that long-
term or high doses of NAM are detrimental because they favor
the development of a fatty liver, due to reductions in available
methyl groups (Kang-Lee et al., 1983). For instance, NAMadmin-
istration for 8 weeks (1–4 g/kg) resulted in methyl group defi-
ciency, which is likely due to the conversion of NAM into
1-methyl-NAM (mNAM) by nicotinamide n-methyltransferase
(NNMT) (Figure 3A). NNMT shunts NAM away from NAD+ using
S-adenosylmethionine (SAM) as a methyl donor (Aksoy et al.,
1994; Riederer et al., 2009). In line with this hypothesis, supple-
mentation of methionine, a methyl group donor, prevented theformation of steatohepatosis caused by high doses of NAM
(Kang-Lee et al., 1983).
Recently, NNMT expression was found to be negatively corre-
lated with GLUT4, the insulin-responsive glucose transporter, in
adipose tissue (Kraus et al., 2014). In adipose-specific Glut4-KO
mice, Nnmt transcripts are increased, while they are reduced in
adipose-specific Glut4-overexpressing mice Nnmt (Kraus et al.,
2014). Similarly, Nnmt transcripts were increased in the WAT of
ob/ob, db/db, and high-fat-fed mice compared to lean insulin-
sensitive controls (Kraus et al., 2014). In addition, tissue specific
knockdown of Nnmt in WAT and liver, using antisense oligonu-
cleotides, protected against diet-induced obesity by increasing
the expression of Sirt1 target genes and energy expenditure.
Accordingly, treating adipocytes with mNAM, which acts as an
end product inhibitor of NNMT (Aksoy et al., 1994), increased
O2 consumption (Kraus et al., 2014). Coming from a totally
different angle, a germline mouse model deficient in Maf1, a
repressor of RNA polymerase III transcription of highly abundant
cellular RNAs (Upadhya et al., 2002), also underscored the
importance of NNMT in NAD+ homeostasis. Maf1/ mice are
resistant to obesity due to metabolic inefficiency as a conse-
quence of futile tRNA production, which led to extreme reduc-
tions of NNMT levels, boosting NAM salvage to regenerate
NAD+ (Bonhoure et al., 2015). In combination, these independent
studies in widely different mouse models support that NNMT
inhibition enhances NAD+-dependent SIRT1 activity and pro-
tects mice against obesity and type 2 diabetes. In a seemingly
contradictory fashion, work in C. elegans has shown that
NNMT and the methylation of NAM might actually be an integral
part of the mechanism by which sirtuins provide healthspan
and lifespan benefits (Schmeisser et al., 2013). For this,
NNMT-produced mNAM would act as a substrate to the
ortholog of the mammalian aldehyde oxidase (AOx1), GAD-3,
to generate hydrogen peroxide, which acts as a mitohormetic
reactive oxygen species signal (Schmeisser et al., 2013). Taken
together, however, NNMT activity seems strongly regulated in
diverse metabolic contexts and has a major impact on NAD+
homeostasis. The discrepancies in the current findings might
arise from the distinct models used (i.e., worms vs. mice) and
the amplitude of the mitohormetic response in different meta-
bolic scenarios.
The Potential for PARP Inhibition in Cell Metabolism. The
potential of PARP inhibition as a treatment for metabolic compli-
cations was first suggested by the observation that Parp1-KO
mice were protected from STZ-induced b cell death and
dysfunction by maintaining NAD+ levels and therefore glucose
tolerance (Masutani et al., 1999). Parp1-KO animals exhibit
higher mitochondrial content, increased energy expenditure,
and protection against metabolic disease brought on by a HFD
(Bai et al., 2011b). Correspondingly, PARP inhibitors also pre-
vent carbon-tetrachloride-induced liver mitochondrial dysfunc-
tion and fibrosis (Mukhopadhyay et al., 2014), and diet-induced
obesity in mice (Pirinen et al., 2014). Long-term treatment of
up to 18 weeks with the dual PARP1 and PARP2 inhibitor
MRL-45696 was shown to enhance exercise capacity and mus-
cle mitochondrial function in chow-diet-fed mice (Cerutti et al.,
2014; Pirinen et al., 2014). Both in worm and mouse models,
the effect of PARP inhibition on mitochondrial function was
linked with the activation of the UPRmt, as reflected by theCell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 41
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oud et al., 2013; Pirinen et al., 2014) (Figure 4). In fact, PARP in-
hibitors increased mitochondrial translation without coordinate
changes in cytosolic translation rates, thus leading to a mitonu-
clear protein imbalance (Pirinen et al., 2014), which in turn
triggers the UPRmt to maintain optimal mitochondrial function
(Houtkooper et al., 2013). This finding is in line with the recent
discovery that mitochondrially located PARP1 activity may
PARylate and disrupt the interaction between key mitochon-
drial-specific DNA base excision repair (BER) enzymes,
namely EXOG andDNApolymerase gamma (Polg), and themito-
chondrial DNA (mtDNA), hindering mitochondrial biogenesis and
reducing mtDNA copy numbers (Szczesny et al., 2014).
While the above observations set the stage for PARP inhibition
to treat complex human metabolic diseases, it is important that
inhibitors are selective for PARP1 and do not affect other mem-
bers of the PARP family. For instance, although Parp2-KO mice
were protected from diet-induced obesity, they were glucose
intolerant due to defective pancreatic function (Bai et al.,
2011a). In this sense, although diverse and highly efficient
PARP inhibitors exist and are currently used in humans for
anti-cancer therapy (Curtin and Szabo, 2013), none of them are
selective for PARP1. Furthermore, since several of the PARPs
play key roles in DNA damage repair upon genotoxic stress
(Curtin and Szabo, 2013), further work must also ensure the
long-term safety of selective PARP1 inhibition to treat metabolic
diseases.
Inhibition of cADP-Ribose Synthases ImprovesMetabolism. As
described above, cADP-Ribose synthases, such as CD38, are
primary NADases in mammalian tissues with a strong impact
on SIRT1 activity (Aksoy et al., 2006a; Escande et al., 2010).
This led to the hypothesis that CD38 inhibition (and subsequent
increases in NAD+ levels) could be applied to treat metabolic
disorders. In line with this, mice lacking CD38 are protected
against diet-induced metabolic disease (Barbosa et al., 2007).
Some natural flavonoids, such as quercetin, apigenin, luteolini-
din, kuromanin, and luteolin, were found to inhibit CD38 in
the low micromolar range (Escande et al., 2013; Kellenberger
et al., 2011). Accordingly, quercetin and apigenin increased liver
NAD+ levels and SIRT1 activity resulting in improved glucose
homeostasis and fatty acid oxidation in the liver of these mice
(Escande et al., 2013). However, the recent development of
potent thiazoloquin(az)olinone inhibitors for CD38, which can
enhance NAD+ levels in multiple tissues, may prove to be effec-
tive for the design of future therapies (Haffner et al., 2015). Yet,
as discussed in NAD+-Consuming Enzymes (III): Cyclic ADP-
Ribose Synthases, there remain several issues that require
further work before CD38 inhibitors can be recommended to
treat metabolic dysfunction. First, it is not entirely clear that
CD38 is the main cADP-ribose synthase enzyme, therefore
potentially compromising the efficacy of CD38 inhibitors for
clinical use. Second, despite evidence indicating that it might
also exist in nuclear and mitochondrial fractions (Aksoy et al.,
2006a), CD38 activity is highest on the extracellular side of the
plasma membrane, where NAD+ levels are generally very low
(De Flora et al., 1997). Finally, the increase in NAD+ observed
in Cd38-deficient mice is 30-fold, while most other strategies
described to date lead to a 2-fold increase in NAD+ at best.
The massive effect of CD38 on NAD+ levels could therefore42 Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc.be indicative for major alterations in additional NAD+-utilizing
metabolic pathways.
New Perspectives in NAD+ Therapeutics (II):
Neurodegenerative Disease
Although theeliminationof neuronsbyaxonal degradationplaysa
role in normal nervous system development, aberrant neuronal
cell death is typical of insults such as trauma, and chemical
toxicity or of aging and neurodegenerative disorders such as Par-
kinson’s disease, Alzheimer’s disease (AD), and amyotrophic
lateral sclerosis (for review, see Wang et al., 2012).
Controversial Links between NMNAT and Neurodegenerative
Phenotypes. Axon degradation had originally been assumed
to be a passive process. However, this view changed with the
characterization of the naturally occurring Wallerian degenera-
tion slow (WldS) dominantmutation (Conforti et al., 2000). Rodent
carriers of this mutation displayed a dramatic reduction in axonal
degeneration in both central and peripheral neurons. The WldS
mutant protein is a chimeric protein composed of the complete
sequence of NMNAT1 fused to the ubiquitination factor E4B at
the N terminus (Conforti et al., 2000; Mack et al., 2001). Efforts
from diverse labs have since confirmed that it is the NMNAT
enzymatic activity that is required to delay axon degeneration
(Araki et al., 2004; Conforti et al., 2009; Gilley and Coleman,
2010; Llopis et al., 2000; Sasaki et al., 2009; Yahata et al.,
2009; Yan et al., 2010), probably by promoting an increase in
NAD+-directed SIRT1 activity (Araki et al., 2004). Interestingly,
WldS mutant mice exhibit enhanced insulin secretion from iso-
lated islets with an improvement in glucose homeostasis, also
via an NAD+-directed activation of SIRT1 (Wu et al., 2011).
Another study specifically demonstrated that it is the cytosolic
distribution of NMNAT proteins that is crucial for slowing
Wallerian degeneration (Sasaki et al., 2009). Further work should
define changes in nuclear and cytosolic NAD+ levels, as most
studies measure NAD+ in whole brain lysate, the outcome of
which is confounded by the high level of NAD+ found in neuronal
mitochondria.
NAD+ Precursors Protect against Neurodegenerative Disease.
Following the injury of neurons, there is an induction of multiple
transcripts for NAD+ biosynthetic enzymes, including a more
than 20-fold increase in NRK2, which catalyzes the synthesis
of NAD+ from NR, suggesting a compensatory response to
elevate NAD+ levels (Sasaki et al., 2006). In line with this, the
pretreatment of neurons with either high levels of NAD+ in cell
culture, or precursors such as NMN or NR, protects against
axonal degeneration following axotomy, hearing loss caused
by excess manganese toxicity, or even noise-induced hearing
loss in mice (Brown et al., 2014; Gerdts et al., 2015; Sasaki
et al., 2006; Wang et al., 2014b). Similarly, rodent studies have
demonstrated that pharmacological doses of NAM increases
NAD+ biosynthesis and provides protection against ischemia
(Klaidman et al., 2003; Sadanaga-Akiyoshi et al., 2003), fetal-
alcohol-induced neurodegeneration (Ieraci and Herrera, 2006),
and fetal ischemic brain injuries (Feng et al., 2006) by preventing
NAD+ depletion. Further supporting the role of NAD+ in neuro-
protection, a high-throughput screen identified an aminopropyl
carbazole chemical P7C3 (Pieper et al., 2010), which was only
recently discovered to be a pharmacological activator of NAMPT
(Wang et al., 2014a), but had previously been shown to possess
neuroprotective activity in models of traumatic brain injury
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2012), and amyotrophic lateral sclerosis (Tesla et al., 2012).
Increasing the activity of existing NAMPT using similar pharma-
cological approaches may therefore improve NAD+ depletion
in aged animals, exhibiting reduced NAMPT and impairments
in neural stem/progenitor cell self-renewal and differentiation,
a treatment phenomenon already demonstrated using NMN
on aging mice (Stein and Imai, 2014). In another model of
neuronal degeneration, raised NAD+ levels after CR attenuated
increases in AD-type b-amyloid content in a rodent model of
AD (Qin et al., 2006). NAM was also able to improve b-amyloid
peptide (1–42)-induced oxidative damage and therefore protect
against neurodegeneration (Turunc Bayrakdar et al., 2014a; Tur-
unc Bayrakdar et al., 2014b). Similarly, exposing neuronal cells
to toxic prion proteins, tomodel proteinmisfolding in Alzheimer’s
and Parkinson’s disease, induced NAD+ depletion that was
improved with exogenous NAD+ or NAM (Zhou et al., 2015).
Additionally, NR has been shown to improve the AD phenotype
via PGC-1a-mediated b-secretase (BACE1) degradation and
the induction of mitochondrial biogenesis (Gong et al., 2013).
Maintaining NAD+ levels seems to, hence, sustain basal meta-
bolic function and health in neurons. Furthermore, based on the
preliminary evidence above, NR might have a privileged position
among different NAD+ precursors in the prevention of neurode-
generation, as the effect of NRmay be enhanced by the increase
in NRK2 during axonal damage.
The Role of PARPs in Neurodegeneration. The depletion of
NAD+ in neurodegeneration has been generally attributed to
the activation of PARP enzymes.Well-known neurodegenerative
DNA repair disorders include ataxia-telangiectasia (AT), Cock-
ayne syndrome (CS), and xeroderma pigmentosum group A
(XPA), all of which demonstrate mitochondrial dysregulation
due to SIRT1 inhibition and a reduction in mitophagy, the pro-
cess of autophagic clearance of defective mitochondria (Fang
et al., 2014). The reduction in SIRT1 activity and mitophagy in
XPA-, CSB-, and ATM-deficient cells can be attributed to the
aberrant activation of PARP1, as reflected by the ability of
PARP inhibitor AZD2281 (olaparib) to rescue the mitochondrial
defect in cells and to extend the lifespan of xpa-1mutant worms
(Fang et al., 2014). In extension of these findings, using NR or a
PARP inhibitor both improved the phenotype of a mouse model
of Cockayne Syndrome group B (CSB), an accelerated aging
disorder featuring the disinhibition of PARP activity by CSB pro-
tein, through SIRT1-mediated improvements of metabolic, mito-
chondrial, and transcriptional alterations (Scheibye-Knudsen
et al., 2014). Similarly, augmented PARylation in the Csa//
Xpa/ (CX) mouse model of cerebellar ataxia was reduced
upon NR treatment, which improved NAD+ levels, SIRT1 activity,
andmitochondrial function (Fang et al., 2014). Both interventions
usingNAD+ precursors or PARP inhibition could hence be helpful
to improve neurodegenerative phenotypes.
NewPerspectives in NAD+ Therapeutics (III): Cancer and
Cell Fate
Genomic stress is the root of all cancers, and so maintaining
genome integrity is an essential tool for the prevention of cancer.
The fact that PARPs and several sirtuin enzymes are key for
genomic maintenance suggests that the regulation of NAD+
could have an impact on cancer susceptibility and development
(Canto´ et al., 2013). As protectors of genomic stability, PARPscan potentially play a multifunctional role in various cancer-
related processes, including DNA repair, recombination, cell
proliferation, or cell death. In general, PARP activity protects
cancer cells, especially those with high genome instability,
from cellular death. Thus, PARP inhibitors are currently being
clinically studied for the treatment of cancers that result from
dysfunctional homologous DNA recombination repair (Curtin
and Szabo, 2013). While a role for SIRT1 in cancer has been
controversial, transgenic animal models demonstrate that
SIRT1 protects against age-related carcinomas and sarcomas,
but not lymphomas (Herranz et al., 2010). Given that PARP
activity is rarely affected by physiological changes in NAD+
availability, it would be intuitive to think that most effects derived
from fluctuations in NAD+ levels might crystalize into expected
outcomes of modulating the activity of some sirtuins, such as
SIRT1 (i.e., protection against cancer). In this sense, it has
been demonstrated that niacin supplementation can decrease
the development of skin cancer (Gensler et al., 1999), while
NR can both reduce the incidence of cancer and have a thera-
peutic effect on fully formed tumors in a genetic mouse model
for liver cancer (Tummala et al., 2014). Conversely, niacin defi-
ciency can enhance cancer susceptibility, indicating that cellular
NAD+ levels are inversely related to the incidence of cancer
(Benavente et al., 2012; Jacobson, 1993). In another approach,
some evidence suggests that the protective effects of niacin
against the development of skin cancer are due to elevation in
both PARPs and SIRT1 activity (Benavente et al., 2012). First,
niacin can effectively restore NAD+ levels and Poly(ADP)-ribosy-
lated proteins in keratinocytes following photodamage, indi-
cating an increase in the activity of PARPs. Second, SIRT1,
also related to DNA repair and maintaining genomic stability
and nucleotide excision repair pathways (Fan and Luo, 2010;
Wang et al., 2008), exhibited increased activity in this same
model, as evidenced by increased protein deacetylation. How-
ever, the balance of SIRT1 and PARP activities upon genotoxic
stress is further complicated by the fact that SIRT1 may reduce
the expression or be a direct inhibitor of PARP1 (Kolthur-See-
tharam et al., 2006; Rajamohan et al., 2009), and PARP2 is a
negative regulator of SIRT1 expression (Bai et al., 2011a). This
emphasizes the potential for an NAD+-dependent failsafe mech-
anism that can decide to elicit either repair or apoptosis depend-
ing on the severity of the cellular genotoxic insult through the
manipulation and balance of SIRT1 and PARP activity levels.
Furthermore, SIRT6, which, as described above, most likely
does not act as anNAD+ sensor (see NAD+-Consuming Enzymes
(I): Sirtuins), can activate PARP1 to stimulate highly efficient dou-
ble-strand break repair, but only in response to oxidative-stress-
induced DNA damage (Mao et al., 2011). In addition, SIRT3
and SIRT5 have both been shown to play roles as either tumor
suppressors or oncogenes depending on the cellular andmolec-
ular context, while SIRT4 acts as a tumor repressor due to its
repression of glutamine metabolism, a process that is essential
during rapid cell proliferation, as is seen in cancer (reviewed in
Kumar and Lombard, 2015).
In a more speculative territory, it should also be highlighted
that higher NAD+ levels, either through PARP inhibition or NAD+
precursor supplementation, rewire metabolism and enhance
oxidative versus glycolytic metabolism. Most cancer cells rely
indisputably on glycolytic metabolism. Therefore, the metabolicCell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 43
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mentary mechanism to slow down cancer progression or initiate
cell death. However, NAD+ depletion might also inhibit growth
of several cancers. NAMPT has been found to be overexpressed
in several types of tumors, and its expression is associated
to tumor progression (Bi et al., 2011; Hasmann and Schemainda,
2003; Van Beijnum et al., 2002; Wang et al., 2011). Conse-
quently, several studies showed that the NAD+ depletion trig-
gered by the downregulation of NAMPT activity can reduce
tumor cell growth and sensitize cells to chemotoxic agents
(Bi et al., 2011; Hasmann and Schemainda, 2003; Wang et al.,
2011; Watson et al., 2009). One must keep in mind that, in
most cancer cells, PARPs are activated due to DNA damage
and genome instability, leading to NAD+ depletion in cancer cells
(Garten et al., 2009). As a result, the downregulation of NAMPT
sensitizes cancer cells to DNA-damaging agents and apoptosis.
In addition, NAD+ depletion also impairs glycolytic capacity in
tumor cells (Bai and Canto´, 2012). Altogether, the above data
suggest that both NAD+-boosting and depletion can impact on
tumor development and progression depending on the type
and the metabolic properties of the tumor.
New Perspectives in NAD+ Therapeutics (IV): Aging
We have only recently started to understand the key pathways
involved in defining lifespan. Much of this insight came from
studies on CR, the most consistent intervention that extends
longevity (as reviewed in Canto´ and Auwerx, 2009). Despite
some evidence disputing the link between sirtuins and the
longevity effects of CR, or longevity in general (Burnett et al.,
2011; Jiang et al., 2000; Lamming et al., 2005), most data agree
that sirtuin activation in mammals delays the onset of age-
related degenerative processes (Herranz et al., 2010; Kanfi
et al., 2012; Pearson et al., 2008; Satoh et al., 2013) and that
defective sirtuin activity impairs some of themetabolic and phys-
iological benefits triggered by CR (Boily et al., 2008; Hallows
et al., 2011; Mercken et al., 2013; Someya et al., 2010).
Of note, SIRT1 and SIRT3 have so far been the sirtuins most
tightly linked to adaptations during CR. As discussed in NAD+-
Consuming Enzymes (I): Sirtuins, the enzymatic characteristics
of these sirtuins, but not of other sirtuins, may allow them to
act as predominant NAD+ sensors, enabling them to monitor
changes in nutrient availability.
During aging, reductions in NAD+ have been consistently
observed in worms, diverse rodent tissues—including liver,
pancreas, kidney, skeletal muscle, heart, and white adipose—
and in human skin samples (Braidy et al., 2011; Gomes et al.,
2013; Khan et al., 2014; Massudi et al., 2012; Mouchiroud
et al., 2013; Yoshino et al., 2011). Several hypotheses can
explain the reductions in NAD+ levels during aging. The first relies
on reductions in NAMPT expression with age, which may be in
part due to the dysregulation of the circadian rhythm and there-
fore the CLOCK/BMAL regulation of NAMPT (Nakahata et al.,
2009). Another possible explanation for this lies in the higher
PARP activity (due to cumulative DNA damage or alternative
pathways of PARP activation, such as inflammatory or metabolic
stress) observed in old worms and tissues from aged mice
(Braidy et al., 2011; Mouchiroud et al., 2013). Supporting this
possibility, blocking PARP activity is enough to recover NAD+
levels in aged organisms (Mouchiroud et al., 2013). The age-
related reduction in NAD+, in turn, compromises mitochondrial44 Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc.function, which can be recovered via PARP inhibition or NAD+
precursor supplementation (Gomes et al., 2013; Mouchiroud
et al., 2013). These observations are in line with the protection
from metabolic dysfunction and disease in mice with genetically
or pharmacologically triggered deficiencies in PARP activity (Bai
et al., 2011b; Pirinen et al., 2014) or in mice treated with NR
(Canto´ et al., 2012) or NMN (Yoshino et al., 2011). As found in
natural aging, significant reductions in skeletal muscle NAD+
occur in Deletor mice, a mouse model containing a mutation in
the mitochondrial replicative helicase Twinkle, resulting in the
accumulation of damage and a progressive muscle myopathy
(Khan et al., 2014). Treatment of Deletor mice with NR delayed
early- and late-stage disease progression by increasing mito-
chondrial biogenesis in skeletal muscle and brown adipose
tissue while preventing mtDNA damage (Khan et al., 2014). In
line with this, NR and PARP inhibition also improve the respira-
tory chain defect and exercise intolerance in Sco2 knockout/
knockin mice, another model for mitochondrial disease (Cerutti
et al., 2014). Altogether, the above data demonstrate that
NAD+ supplementation maintains mitochondrial function, not
only upon age-related decline but also in genetically determined
mitochondrial diseases that are known to accelerate the aging
process (Figure 4).
The Induction of UPRmt by NAD+ as a Mechanism to Enhance
Longevity. The ability of NAD+ to induce a mitonuclear pro-
tein imbalance could provide a key link between NAD+ and
mitochondrial function. Mitonuclear protein imbalance can be
defined as a stoichiometric difference between nuclear and
mitochondrial-encoded respiratory subunit proteins (Houtkooper
et al., 2013), an effect known to promote longevity in worms (Dur-
ieux et al., 2011; Houtkooper et al., 2013). Forced expression of
genes regulating UPRmt, such as Hsp60 paralogs, in Drosophila
slows age-dependent mitochondrial and muscle dysfunction
due to the compensatory actions of UPRmt signaling (Owusu-
Ansah et al., 2013). Likewise, the activation of the UPRmt by tar-
geting mitochondrial ribosomal protein (Mrp) translation, using
a knockdown of ribosomal proteins or antibiotics that specifically
inhibitmitochondrial translation, increases longevity inC. elegans
(Houtkooper et al., 2013). Strikingly, even subtle changes
in expression levels of the Mrp’s in the BXD mouse genetic
reference population have robust effects on mouse lifespan
(Houtkooper et al., 2010b; Wu et al., 2014). Similarly, both NR
and PARP inhibitors increased C. elegans lifespan via an induc-
tion of the UPRmt by Sir-2.1, the worm SIRT1 ortholog (Mouchir-
oud et al., 2013). Part of the metabolic decline during aging is
due to a PARP-directed decay in NAD+ levels, leading to reduced
SIRT1, or Sir-2.1, activity and subsequent reduction in FOXO3A/
Daf-16 activity and anti-oxidant defense (Mouchiroud et al., 2013)
and increased HIF1a-led glycolytic reliance (Gomes et al., 2013).
Furthermore, Sir-2.1-directed longevity is blunted in worms defi-
cient in ubl-5 (Mouchiroud et al., 2013), an essential component
for UPRmt-directed communication from the mitochondria to
the nucleus (Durieux et al., 2011), solidifying the necessity of
UPRmt induction for NAD+-induced longevity. In this sense, the
decline in NAD+ observedwith aging deregulates themitonuclear
protein balance and respiratory function, which accelerates
the aging process. Importantly, mitochondrial dysfunction in
aged mice or worms could be recovered following NMN or
NR treatment (Gomes et al., 2013; Mouchiroud et al., 2013). The
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hormetic response as long as the cell is properly furnished with
NAD+. However, in situations of limited NAD+ availability, SIRT1
fails to drive mitohormesis and, hence, mitochondria remain
dysfunctional. As a whole, the above demonstrates a tight feed-
back loop between themitonuclear protein imbalance andUPRmt
on the one hand and NAD+ metabolism and SIRT1 activity on the
other. In summary, this assigns a crucial role for NAD+ to synchro-
nize the nuclear and mitochondrial genomes.
The identification of UPRmt as a main mechanism by which
NAD+ levels modulate mitochondrial fitness constitutes a major
leap forward in our understanding of the molecular mechanisms
driving a healthy lifespan. Importantly, UPRmt is not just the prin-
ciple mechanism by which NAD+ affects longevity, but is also a
key mode of action for other well-studied longevity compounds,
such as rapamycin and resveratrol (Houtkooper et al., 2013).Conclusions
The association between metabolism, health, and lifespan have
long been proposed based on similarities between metabolic
dysfunction and disease (e.g., obesity, diabetes, neurodegener-
ation, and cancer) and the aging process. Only recently have
these processes been linked so tightly by multiple proteins,
including sirtuins and PARPs, all of which are tightly controlled
by the regulation and subcellular balance of the metabolite
NAD+. As such, we have never been so close to solving the
ancient question of how we age and what we can do to slow
this process while simultaneously not compromising on our
quality of life. Despite these insights, several aspects of NAD+
metabolism remain obscure. On one side, the complex detection
and quantification of NAD+ metabolites and fluxes has not
yet allowed us to obtain a clear picture of how different NAD+
precursors are metabolized to feed cells and tissues. We also
speculate that additional proteins controlling the supply
or salvage of NAD+, along with proteins that are controlled
by NAD+ levels, will be identified. Furthermore, the potential
preventive and therapeutic use of NAD+-boosting strategies
requires an assessment of the bioavailability and effectiveness
of various precursor doses in human therapy. In addition, new
NAD+ boosters are welcomed since the side effects of niacin
generally lead to poor compliance, despite its known efficacy
in a myriad of diseases. Therefore, the dosing and safety
of these new NAD+ boosters (e.g., NAD+ precursors, CD38
inhibitors, and PARP inhibitors) must be thoroughly assessed
to translate these exciting insights into NAD+ biology toward
human relevance.AUTHOR CONTRIBUTIONS
C.C. and K.J.M. both designed the outline and wrote the text. J.A. contributed
to the ideas that make up this review and provided edits to all sections.ACKNOWLEDGMENTS
We would like to kindly thank Yoh Terada for his helpful advice during
the creation of this review. K.J.M. is the recipient of a Heart and Stroke Foun-
dation of Canada research fellowship award. C.C. is an employee of the
Nestle´ Institute of Health Sciences S.A. J.A. is the Nestle´ Chair in Energy
Metabolism. Work in the laboratory is supported by the E´cole Polytechnique
Fe´de´rale de Lausanne, the National Institutes of Health (R01AG043930),the Swiss National Science Foundation (31003A-124713), and Systems X
(51RTP0-151019).
REFERENCES
Aksoy, S., Szumlanski, C.L., andWeinshilboum, R.M. (1994). Human liver nico-
tinamide N-methyltransferase. cDNA cloning, expression, and biochemical
characterization. J. Biol. Chem. 269, 14835–14840.
Aksoy, P., Escande, C., White, T.A., Thompson, M., Soares, S., Benech, J.C.,
and Chini, E.N. (2006a). Regulation of SIRT 1 mediated NAD dependent
deacetylation: a novel role for themultifunctional enzymeCD38. Biochem. Bio-
phys. Res. Commun. 349, 353–359.
Aksoy, P., White, T.A., Thompson, M., and Chini, E.N. (2006b). Regulation of
intracellular levels of NAD: a novel role for CD38. Biochem. Biophys. Res.
Commun. 345, 1386–1392.
Alano, C.C., Tran, A., Tao, R., Ying, W., Karliner, J.S., and Swanson, R.A.
(2007). Differences among cell types in NAD(+) compartmentalization: a com-
parison of neurons, astrocytes, and cardiac myocytes. J. Neurosci. Res. 85,
3378–3385.
Alano, C.C., Garnier, P., Ying, W., Higashi, Y., Kauppinen, T.M., and Swanson,
R.A. (2010). NAD+ depletion is necessary and sufficient for poly(ADP-ribose)
polymerase-1-mediated neuronal death. J. Neurosci. 30, 2967–2978.
Altschul, R., Hoffer, A., and Stephen, J.D. (1955). Influence of nicotinic acid on
serum cholesterol in man. Arch. Biochem. Biophys. 54, 558–559.
Ame´, J.C., Rolli, V., Schreiber, V., Niedergang, C., Apiou, F., Decker, P., Muller,
S., Ho¨ger, T., Me´nissier-de Murcia, J., and de Murcia, G. (1999). PARP-2, A
novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase.
J. Biol. Chem. 274, 17860–17868.
Anderson, R.M., Bitterman, K.J., Wood, J.G., Medvedik, O., and Sinclair, D.A.
(2003). Nicotinamide and PNC1 govern lifespan extension by calorie restriction
in Saccharomyces cerevisiae. Nature 423, 181–185.
Andrabi, S.A., Umanah, G.K.E., Chang, C., Stevens, D.A., Karuppagounder,
S.S., Gagne´, J.-P., Poirier, G.G., Dawson, V.L., and Dawson, T.M. (2014).
Poly(ADP-ribose) polymerase-dependent energy depletion occurs through in-
hibition of glycolysis. Proc. Natl. Acad. Sci. USA 111, 10209–10214.
Araki, T., Sasaki, Y., and Milbrandt, J. (2004). Increased nuclear NAD biosyn-
thesis and SIRT1 activation prevent axonal degeneration. Science 305, 1010–
1013.
Asher, G., Gatfield, D., Stratmann, M., Reinke, H., Dibner, C., Kreppel, F., Mos-
toslavsky, R., Alt, F.W., and Schibler, U. (2008). SIRT1 regulates circadian
clock gene expression through PER2 deacetylation. Cell 134, 317–328.
Asher, G., Reinke, H., Altmeyer, M., Gutierrez-Arcelus, M., Hottiger, M.O., and
Schibler, U. (2010). Poly(ADP-ribose) polymerase 1 participates in the phase
entrainment of circadian clocks to feeding. Cell 142, 943–953.
Bacher, I., Zidar, A., Kratzel, M., and Hohenegger, M. (2004). Channelling of
substrate promiscuity of the skeletal-muscle ADP-ribosyl cyclase isoform.
Biochem. J. 381, 147–154.
Bai, P., and Canto´, C. (2012). The role of PARP-1 and PARP-2 enzymes in
metabolic regulation and disease. Cell Metab. 16, 290–295.
Bai, P., Canto, C., Brunya´nszki, A., Huber, A., Sza´nto´, M., Cen, Y., Yamamoto,
H., Houten, S.M., Kiss, B., Oudart, H., et al. (2011a). PARP-2 regulates SIRT1
expression and whole-body energy expenditure. Cell Metab. 13, 450–460.
Bai, P., Canto´, C., Oudart, H., Brunya´nszki, A., Cen, Y., Thomas, C., Yama-
moto, H., Huber, A., Kiss, B., Houtkooper, R.H., et al. (2011b). PARP-1 inhibi-
tion increases mitochondrial metabolism through SIRT1 activation. Cell
Metab. 13, 461–468.
Banks, A.S., Kon, N., Knight, C., Matsumoto, M., Gutie´rrez-Jua´rez, R., Ros-
setti, L., Gu, W., and Accili, D. (2008). SirT1 gain of function increases energy
efficiency and prevents diabetes in mice. Cell Metab. 8, 333–341.
Bao, X.,Wang, Y., Li, X., Li, X.-M., Liu, Z., Yang, T., Wong, C.F., Zhang, J., Hao,
Q., and Li, X.D. (2014). Identification of ‘erasers’ for lysine crotonylated histone
marks using a chemical proteomics approach. Elife 3, http://dx.doi.org/10.
7554/eLife.02999.Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 45
Cell Metabolism
ReviewBarbosa, M.T.P., Soares, S.M., Novak, C.M., Sinclair, D., Levine, J.A., Aksoy,
P., and Chini, E.N. (2007). The enzyme CD38 (a NAD glycohydrolase, EC
3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J.
21, 3629–3639.
Barile, M., Passarella, S., Danese, G., and Quagliariello, E. (1996). Rat liver
mitochondria can synthesize nicotinamide adenine dinucleotide from nicotin-
amide mononucleotide and ATP via a putative matrix nicotinamide mononu-
cleotide adenylyltransferase. Biochem. Mol. Biol. Int. 38, 297–306.
Bauer, J.H., Morris, S.N.S., Chang, C., Flatt, T., Wood, J.G., and Helfand, S.L.
(2009). dSir2 and Dmp53 interact to mediate aspects of CR-dependent life-
span extension in D. melanogaster. Aging (Albany, N.Y. Online) 1, 38–48.
Baum, C.L., Selhub, J., and Rosenberg, I.H. (1982). The hydrolysis of nicotin-
amide adenine nucleotide by brush border membranes of rat intestine. Bio-
chem. J. 204, 203–207.
Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A.,
Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K., et al. (2006). Resveratrol
improves health and survival of mice on a high-calorie diet. Nature 444,
337–342.
Beirowski, B., Gustin, J., Armour, S.M., Yamamoto, H., Viader, A., North, B.J.,
Micha´n, S., Baloh, R.H., Golden, J.P., Schmidt, R.E., et al. (2011). Sir-two-ho-
molog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-
3/atypical protein kinase C (aPKC) signaling. Proc. Natl. Acad. Sci. USA 108,
E952–E961.
Belenky, P., Racette, F.G., Bogan, K.L., McClure, J.M., Smith, J.S., and Bren-
ner, C. (2007). Nicotinamide riboside promotes Sir2 silencing and extends life-
span via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell 129, 473–484.
Benavente, C.A., Jacobson, M.K., and Jacobson, E.L. (2009). NAD in skin:
therapeutic approaches for niacin. Curr. Pharm. Des. 15, 29–38.
Benavente, C.A., Schnell, S.A., and Jacobson, E.L. (2012). Effects of niacin re-
striction on sirtuin and PARP responses to photodamage in human skin. PLoS
ONE 7, e42276.
Bender, D.A. (1983). Biochemistry of tryptophan in health and disease. Mol.
Aspects Med. 6, 101–197.
Benjamin, R.C., and Gill, D.M. (1980). Poly(ADP-ribose) synthesis in vitro pro-
grammed by damaged DNA. A comparison of DNA molecules containing
different types of strand breaks. J. Biol. Chem. 255, 10502–10508.
Benyo´, Z., Gille, A., Kero, J., Csiky, M., Sucha´nkova´, M.C., Nu¨sing, R.M.,
Moers, A., Pfeffer, K., and Offermanns, S. (2005). GPR109A (PUMA-G/
HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest. 115, 3634–
3640.
Berger, N.A. (1985). Poly(ADP-ribose) in the cellular response to DNA damage.
Radiat. Res. 101, 4–15.
Berger, F., Lau, C., Dahlmann, M., and Ziegler, M. (2005). Subcellular compart-
mentation and differential catalytic properties of the three human nicotinamide
mononucleotide adenylyltransferase isoforms. J. Biol. Chem. 280, 36334–
36341.
Bessede, A., Gargaro, M., Pallotta, M.T., Matino, D., Servillo, G., Brunacci, C.,
Bicciato, S., Mazza, E.M.C., Macchiarulo, A., Vacca, C., et al. (2014). Aryl hy-
drocarbon receptor control of a disease tolerance defence pathway. Nature
511, 184–190.
Bi, T.-Q., Che, X.-M., Liao, X.-H., Zhang, D.-J., Long, H.-L., Li, H.-J., and Zhao,
W. (2011). Overexpression of Nampt in gastric cancer and chemopotentiating
effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol.
Rep. 26, 1251–1257.
Bieganowski, P., and Brenner, C. (2004). Discoveries of nicotinamide riboside
as a nutrient and conserved NRK genes establish a Preiss-Handler indepen-
dent route to NAD+ in fungi and humans. Cell 117, 495–502.
Birjmohun, R.S., Hutten, B.A., Kastelein, J.J., and Stroes, E.S. (2005). Efficacy
and safety of high-density lipoprotein cholesterol-increasing compounds: a
meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 45,
185–197.
Bitterman, K.J., Anderson, R.M., Cohen, H.Y., Latorre-Esteves, M., and Sin-
clair, D.A. (2002). Inhibition of silencing and accelerated aging by nicotinamide,
a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem.
277, 45099–45107.46 Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc.Blander, G., and Guarente, L. (2004). The Sir2 family of protein deacetylases.
Annu. Rev. Biochem. 73, 417–435.
Bobrowska, A., Donmez, G., Weiss, A., Guarente, L., and Bates, G. (2012).
SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosyn-
thesis or the progression of Huntington’s disease phenotypes in vivo. PLoS
ONE 7, e34805.
Bogan, K.L., and Brenner, C. (2008). Nicotinic acid, nicotinamide, and nicotin-
amide riboside: a molecular evaluation of NAD+ precursor vitamins in human
nutrition. Annu. Rev. Nutr. 28, 115–130.
Boily, G., Seifert, E.L., Bevilacqua, L., He, X.H., Sabourin, G., Estey, C., Moffat,
C., Crawford, S., Saliba, S., Jardine, K., et al. (2008). SirT1 regulates energy
metabolism and response to caloric restriction in mice. PloS One 3, http://
dx.doi.org/10.1371/journal.pone.0001759.
Bonhoure, N., Byrnes, A., Moir, R.D., Hodroj, W., Preitner, F., Praz, V., Marce-
lin, G., Chua, S.C., Jr., Martinez-Lopez, N., Singh, R., et al. (2015). Loss of the
RNA polymerase III repressor MAF1 confers obesity resistance. Genes Dev.
29, 934–947.
Borra, M.T., Langer, M.R., Slama, J.T., and Denu, J.M. (2004). Substrate spec-
ificity and kinetic mechanism of the Sir2 family of NAD+-dependent histone/
protein deacetylases. Biochemistry 43, 9877–9887.
Boutant, M., and Canto, C. (2014). SIRT1 metabolic actions: Integrating recent
advances from mouse models. Mol. Metab. 3, 5–18.
Braidy, N., Guillemin, G.J., Mansour, H., Chan-Ling, T., Poljak, A., and Grant,
R. (2011). Age related changes in NAD+ metabolism oxidative stress and Sirt1
activity in wistar rats. PLoS ONE 6, e19194.
Brown, K.D., Maqsood, S., Huang, J.-Y., Pan, Y., Harkcom, W., Li, W., Sauve,
A., Verdin, E., and Jaffrey, S.R. (2014). Activation of SIRT3 by the NAD+ precur-
sor nicotinamide riboside protects from noise-induced hearing loss. Cell
Metab. 20, 1059–1068.
Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E.,
Kyle, S., Meuth, M., Curtin, N.J., and Helleday, T. (2005). Specific killing
of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Nature 434, 913–917.
Burnett, C., Valentini, S., Cabreiro, F., Goss, M., Somogyva´ri, M., Piper, M.D.,
Hoddinott, M., Sutphin, G.L., Leko, V., McElwee, J.J., et al. (2011). Absence of
effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature
477, 482–485.
Cabrera-Rode, E., Molina, G., Arranz, C., Vera, M., Gonza´lez, P., Sua´rez, R.,
Prieto, M., Padro´n, S., Leo´n, R., Tillan, J., et al. (2006). Effect of standard nico-
tinamide in the prevention of type 1 diabetes in first degree relatives of persons
with type 1 diabetes. Autoimmunity 39, 333–340.
Cakir-Kiefer, C., Muller-Steffner, H., Oppenheimer, N., and Schuber, F. (2001).
Kinetic competence of the cADP-ribose-CD38 complex as an intermediate in
the CD38/NAD+ glycohydrolase-catalysed reactions: implication for CD38
signalling. Biochem. J. 358, 399–406.
Canto´, C., and Auwerx, J. (2009). Caloric restriction, SIRT1 and longevity.
Trends Endocrinol. Metab. 20, 325–331.
Canto´, C., and Auwerx, J. (2012). Targeting sirtuin 1 to improve metabolism: all
you need is NAD(+). Pharmacol. Rev. 64, 166–187.
Canto´, C., Gerhart-Hines, Z., Feige, J.N., Lagouge, M., Noriega, L., Milne, J.C.,
Elliott, P.J., Puigserver, P., and Auwerx, J. (2009). AMPK regulates energy
expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature
458, 1056–1060.
Canto´, C., Jiang, L.Q., Deshmukh, A.S., Mataki, C., Coste, A., Lagouge, M.,
Zierath, J.R., and Auwerx, J. (2010). Interdependence of AMPK and SIRT1
formetabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab.
11, 213–219.
Canto´, C., Houtkooper, R.H., Pirinen, E., Youn, D.Y., Oosterveer, M.H., Cen,
Y., Fernandez-Marcos, P.J., Yamamoto, H., Andreux, P.A., Cettour-Rose,
P., et al. (2012). The NAD(+) precursor nicotinamide riboside enhances oxida-
tive metabolism and protects against high-fat diet-induced obesity. Cell
Metab. 15, 838–847.
Canto´, C., Sauve, A.A., andBai, P. (2013). Crosstalk between poly(ADP-ribose)
polymerase and sirtuin enzymes. Mol. Aspects Med. 34, 1168–1201.
Cell Metabolism
ReviewCeni, C., Muller-Steffner, H., Lund, F., Pochon, N., Schweitzer, A., De Waard,
M., Schuber, F., Villaz, M., and Moutin, M.J. (2003). Evidence for an intracel-
lular ADP-ribosyl cyclase/NAD+-glycohydrolase in brain from CD38-deficient
mice. J. Biol. Chem. 278, 40670–40678.
Cerutti, R., Pirinen, E., Lamperti, C., Marchet, S., Sauve, A.A., Li, W., Leoni, V.,
Schon, E.A., Dantzer, F., Auwerx, J., et al. (2014). NAD(+)-dependent activa-
tion of Sirt1 corrects the phenotype in a mouse model of mitochondrial dis-
ease. Cell Metab. 19, 1042–1049.
Chang, H.-C., and Guarente, L. (2013). SIRT1 mediates central circadian con-
trol in the SCN by a mechanism that decays with aging. Cell 153, 1448–1460.
Chen, D., Bruno, J., Easlon, E., Lin, S.J., Cheng, H.L., Alt, F.W., and Guarente,
L. (2008). Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev.
22, 1753–1757.
Chen, S., Seiler, J., Santiago-Reichelt, M., Felbel, K., Grummt, I., and Voit, R.
(2013). Repression of RNA polymerase I upon stress is caused by inhibition of
RNA-dependent deacetylation of PAF53 by SIRT7. Mol. Cell 52, 303–313.
Chi, Y., and Sauve, A.A. (2013). Nicotinamide riboside, a trace nutrient in
foods, is a vitamin B3 with effects on energy metabolism and neuroprotection.
Curr. Opin. Clin. Nutr. Metab. Care 16, 657–661.
Chiang, Y.J., Nguyen, M.-L., Gurunathan, S., Kaminker, P., Tessarollo, L.,
Campisi, J., and Hodes, R.J. (2006). Generation and characterization of telo-
mere length maintenance in tankyrase 2-deficient mice. Mol. Cell. Biol. 26,
2037–2043.
Cohen-Armon, M., Visochek, L., Rozensal, D., Kalal, A., Geistrikh, I., Klein, R.,
Bendetz-Nezer, S., Yao, Z., and Seger, R. (2007). DNA-independent PARP-1
activation by phosphorylated ERK2 increases Elk1 activity: a link to histone
acetylation. Mol. Cell 25, 297–308.
Collins, P.B., and Chaykin, S. (1972). The management of nicotinamide and
nicotinic acid in the mouse. J. Biol. Chem. 247, 778–783.
Conforti, L., Tarlton, A., Mack, T.G., Mi, W., Buckmaster, E.A., Wagner, D.,
Perry, V.H., and Coleman, M.P. (2000). A Ufd2/D4Cole1e chimeric protein
and overexpression of Rbp7 in the slowWallerian degeneration (WldS) mouse.
Proc. Natl. Acad. Sci. USA 97, 11377–11382.
Conforti, L., Wilbrey, A., Morreale, G., Janeckova, L., Beirowski, B., Adalbert,
R., Mazzola, F., Di Stefano,M., Hartley, R., Babetto, E., et al. (2009). Wld S pro-
tein requires Nmnat activity and a short N-terminal sequence to protect axons
in mice. J. Cell Biol. 184, 491–500.
Conforti, L., Janeckova, L., Wagner, D., Mazzola, F., Cialabrini, L., Di Stefano,
M., Orsomando, G., Magni, G., Bendotti, C., Smyth, N., and Coleman, M.
(2011). Reducing expression of NAD+ synthesizing enzyme NMNAT1 does
not affect the rate of Wallerian degeneration. FEBS J. 278, 2666–2679.
Costford, S.R., Bajpeyi, S., Pasarica, M., Albarado, D.C., Thomas, S.C., Xie,
H., Church, T.S., Jubrias, S.A., Conley, K.E., and Smith, S.R. (2010). Skeletal
muscle NAMPT is induced by exercise in humans. Am. J. Physiol. Endocrinol.
Metab. 298, E117–E126.
Curtin, N.J., and Szabo, C. (2013). Therapeutic applications of PARP inhibitors:
anticancer therapy and beyond. Mol. Aspects Med. 34, 1217–1256.
Cynamon, M.H., Sorg, T.B., and Patapow, A. (1988). Utilization and meta-
bolism of NAD by Haemophilus parainfluenzae. J. Gen. Microbiol. 134,
2789–2799.
De Flora, A., Guida, L., Franco, L., and Zocchi, E. (1997). The CD38/cyclic
ADP-ribose system: a topological paradox. Int. J. Biochem. Cell Biol. 29,
1149–1166.
De Jesu´s-Corte´s, H., Xu, P., Drawbridge, J., Estill, S.J., Huntington, P., Tran,
S., Britt, J., Tesla, R., Morlock, L., Naidoo, J., et al. (2012). Neuroprotective ef-
ficacy of aminopropyl carbazoles in a mouse model of Parkinson disease.
Proc. Natl. Acad. Sci. USA 109, 17010–17015.
Devalaraja-Narashimha, K., and Padanilam, B.J. (2010). PARP1 deficiency ex-
acerbates diet-induced obesity in mice. J. Endocrinol. 205, 243–252.
Diani-Moore, S., Ram, P., Li, X., Mondal, P., Youn, D.Y., Sauve, A.A., and
Rifkind, A.B. (2010). Identification of the aryl hydrocarbon receptor target
gene TiPARP as a mediator of suppression of hepatic gluconeogenesis by
2,3,7,8-tetrachlorodibenzo-p-dioxin and of nicotinamide as a corrective agent
for this effect. J. Biol. Chem. 285, 38801–38810.Du, J., Zhou, Y., Su, X., Yu, J.J., Khan, S., Jiang, H., Kim, J., Woo, J., Kim, J.H.,
Choi, B.H., et al. (2011). Sirt5 is a NAD-dependent protein lysine demalonylase
and desuccinylase. Science 334, 806–809.
Durieux, J., Wolff, S., and Dillin, A. (2011). The cell-non-autonomous nature of
electron transport chain-mediated longevity. Cell 144, 79–91.
Elvehjem, C.A. (1940). The Biological Significance of Nicotinic Acid: Harvey
Lecture, November 16, 1939. Bull. N. Y. Acad. Med. 16, 173–189.
Emanuelli, M., Carnevali, F., Saccucci, F., Pierella, F., Amici, A., Raffaelli, N.,
and Magni, G. (2001). Molecular cloning, chromosomal localization, tissue
mRNA levels, bacterial expression, and enzymatic properties of human NMN
adenylyltransferase. J. Biol. Chem. 276, 406–412.
Erener, S., Mirsaidi, A., Hesse, M., Tiaden, A.N., Ellingsgaard, H., Kostadinova,
R., Donath, M.Y., Richards, P.J., and Hottiger, M.O. (2012). ARTD1 deletion
causes increased hepatic lipid accumulation in mice fed a high-fat diet and im-
pairs adipocyte function and differentiation. FASEB J. 26, 2631–2638.
Escande, C., Chini, C.C., Nin, V., Dykhouse, K.M., Novak, C.M., Levine, J., van
Deursen, J., Gores, G.J., Chen, J., Lou, Z., and Chini, E.N. (2010). Deleted in
breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-
induced liver steatosis in mice. J. Clin. Invest. 120, 545–558.
Escande, C., Nin, V., Price, N.L., Capellini, V., Gomes, A.P., Barbosa, M.T.,
O’Neil, L., White, T.A., Sinclair, D.A., and Chini, E.N. (2013). Flavonoid apigenin
is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ meta-
bolism, protein acetylation, and treatment of metabolic syndrome. Diabetes
62, 1084–1093.
Euler-Chelpin, H.v. (1929). Nobel Lecture: Fermentation of Sugars and
Fermentative Enzymes. (http://www.nobelprize.org/nobel_prizes/chemistry/
laureates/1929/euler-chelpin-lecture.html: The Nobel Foundation 1929).
Fan, W., and Luo, J. (2010). SIRT1 regulates UV-induced DNA repair through
deacetylating XPA. Mol. Cell 39, 247–258.
Fang, E.F., Scheibye-Knudsen, M., Brace, L.E., Kassahun, H., SenGupta, T.,
Nilsen, H., Mitchell, J.R., Croteau, D.L., and Bohr, V.A. (2014). Defective mi-
tophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction.
Cell 157, 882–896.
Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N.J., Johnson, D.A., Richardson,
T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., et al. (2005). Targeting
the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature
434, 917–921.
Feige, J.N., Lagouge, M., Canto, C., Strehle, A., Houten, S.M., Milne, J.C.,
Lambert, P.D., Mataki, C., Elliott, P.J., and Auwerx, J. (2008). Specific SIRT1
activation mimics low energy levels and protects against diet-induced meta-
bolic disorders by enhancing fat oxidation. Cell Metab. 8, 347–358.
Feldman, J.L., Baeza, J., and Denu, J.M. (2013). Activation of the protein de-
acetylase SIRT6 by long-chain fatty acids and widespread deacylation by
mammalian sirtuins. J. Biol. Chem. 288, 31350–31356.
Felici, R., Lapucci, A., Ramazzotti, M., and Chiarugi, A. (2013). Insight into mo-
lecular and functional properties of NMNAT3 reveals new hints of NAD homeo-
stasis within human mitochondria. PLoS ONE 8, e76938.
Feng, Y., Paul, I.A., and LeBlanc, M.H. (2006). Nicotinamide reduces hypoxic
ischemic brain injury in the newborn rat. Brain Res. Bull. 69, 117–122.
Fischer, F., Gertz, M., Suenkel, B., Lakshminarasimhan, M., Schutkowski, M.,
and Steegborn, C. (2012). Sirt5 deacylation activities show differential sensitiv-
ities to nicotinamide inhibition. PLoS ONE 7, e45098.
Fjeld, C.C., Birdsong, W.T., and Goodman, R.H. (2003). Differential binding of
NAD+ and NADH allows the transcriptional corepressor carboxyl-terminal
binding protein to serve as a metabolic sensor. Proc. Natl. Acad. Sci. USA
100, 9202–9207.
Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mor-
timer, P., Swaisland, H., Lau, A., O’Connor, M.J., et al. (2009). Inhibition of pol-
y(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J.
Med. 361, 123–134.
Forbes, J.C., and Duncan, G.M. (1961). Effect of a tryptophan-niacin deficient
diet on the adrenal response of rats exposed to cold and alcohol intoxication.
Q. J. Stud. Alcohol 22, 254–260.Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 47
Cell Metabolism
ReviewFouquerel, E., Goellner, E.M., Yu, Z., Gagne´, J.-P., Barbi de Moura, M., Fein-
stein, T., Wheeler, D., Redpath, P., Li, J., Romero, G., et al. (2014). ARTD1/
PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent
of NAD+ depletion. Cell Rep. 8, 1819–1831.
Fulco, M., Cen, Y., Zhao, P., Hoffman, E.P., McBurney, M.W., Sauve, A.A., and
Sartorelli, V. (2008). Glucose restriction inhibits skeletal myoblast differentia-
tion by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev.
Cell 14, 661–673.
Gale, E.A.M., Bingley, P.J., Emmett, C.L., Collier, T., and Group, E.N.D.I.T.E.;
European Nicotinamide Diabetes Intervention Trial (ENDIT) Group (2004).
European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised
controlled trial of intervention before the onset of type 1 diabetes. Lancet
363, 925–931.
Garten,A., Petzold,S., Ko¨rner, A., Imai, S.-i., andKiess,W. (2009).Nampt: linking
NAD biology, metabolism and cancer. Trends Endocrinol. Metab. 20, 130–138.
Gensler, H.L., Williams, T., Huang, A.C., and Jacobson, E.L. (1999). Oral niacin
prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr.
Cancer 34, 36–41.
Gerdts, J., Brace, E.J., Sasaki, Y., DiAntonio, A., and Milbrandt, J. (2015).
Neurobiology. SARM1 activation triggers axon degeneration locally via
NAD+ destruction. Science 348, 453–457.
Gerhart-Hines, Z., Dominy, J.E., Jr., Bla¨ttler, S.M., Jedrychowski, M.P., Banks,
A.S., Lim, J.-H., Chim, H., Gygi, S.P., and Puigserver, P. (2011). The cAMP/
PKA pathway rapidly activates SIRT1 to promote fatty acid oxidation indepen-
dently of changes in NAD(+). Mol. Cell 44, 851–863.
Gibson, B.A., and Kraus, W.L. (2012). New insights into the molecular and
cellular functions of poly(ADP-ribose) and PARPs. Nat. Rev. Mol. Cell Biol.
13, 411–424.
Gilley, J., and Coleman, M.P. (2010). Endogenous Nmnat2 is an essential sur-
vival factor for maintenance of healthy axons. PLoS Biol. 8, e1000300.
Goldberger, J. (2006). The etiology of pellagra. 1914. Public Health Rep. 121
(Suppl 1 ), 77–79, discussion 76.
Gomes, A.P., Price, N.L., Ling, A.J.Y., Moslehi, J.J., Montgomery, M.K., Raj-
man, L., White, J.P., Teodoro, J.S., Wrann, C.D., Hubbard, B.P., et al.
(2013). Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-
mitochondrial communication during aging. Cell 155, 1624–1638.
Gong, B., Pan, Y., Vempati, P., Zhao, W., Knable, L., Ho, L., Wang, J.,
Sastre, M., Ono, K., Sauve, A.A., and Pasinetti, G.M. (2013). Nicotinamide ri-
boside restores cognition through an upregulation of proliferator-activated
receptor-g coactivator 1a regulated b-secretase 1 degradation and mito-
chondrial gene expression in Alzheimer’s mouse models. Neurobiol. Aging
34, 1581–1588.
Gradwohl, G., Me´nissier deMurcia, J.M., Molinete, M., Simonin, F., Koken, M.,
Hoeijmakers, J.H., and deMurcia, G. (1990). The second zinc-finger domain of
poly(ADP-ribose) polymerase determines specificity for single-stranded
breaks in DNA. Proc. Natl. Acad. Sci. USA 87, 2990–2994.
Gross, C.J., and Henderson, L.M. (1983). Digestion and absorption of NAD by
the small intestine of the rat. J. Nutr. 113, 412–420.
Gwirtz, J.A., and Garcia-Casal, M.N. (2014). Processing maize flour and corn
meal food products. Ann. N Y Acad. Sci. 1312, 66–75.
Haffner, C.D., Becherer, J.D., Boros, E.E., Cadilla, R., Carpenter, T., Cowan,
D., Deaton, D.N., Guo, Y., Harrington, W., Henke, B.R., et al. (2015). Discovery,
Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent
CD38 Inhibitors. J. Med. Chem. 58, 3548–3571.
Haigis, M.C., and Sinclair, D.A. (2010). Mammalian sirtuins: biological insights
and disease relevance. Annu. Rev. Pathol. 5, 253–295.
Haigis, M.C., Mostoslavsky, R., Haigis, K.M., Fahie, K., Christodoulou, D.C.,
Murphy, A.J., Valenzuela, D.M., Yancopoulos, G.D., Karow, M., Blander, G.,
et al. (2006). SIRT4 inhibits glutamate dehydrogenase and opposes the effects
of calorie restriction in pancreatic beta cells. Cell 126, 941–954.
Hall, J.A., Dominy, J.E., Lee, Y., and Puigserver, P. (2013). The sirtuin family’s
role in aging and age-associated pathologies. J. Clin. Invest. 123, 973–979.
Hallows, W.C., Yu, W., Smith, B.C., Devries, M.K., Ellinger, J.J., Someya, S.,
Shortreed, M.R., Prolla, T., Markley, J.L., Smith, L.M., et al. (2011). Sirt3 pro-48 Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc.motes the urea cycle and fatty acid oxidation during dietary restriction. Mol.
Cell 41, 139–149.
Hara, N., Yamada, K., Terashima, M., Osago, H., Shimoyama, M., and
Tsuchiya, M. (2003). Molecular identification of human glutamine- and
ammonia-dependent NAD synthetases. Carbon-nitrogen hydrolase domain
confers glutamine dependency. J. Biol. Chem. 278, 10914–10921.
Hara, N., Yamada, K., Shibata, T., Osago, H., Hashimoto, T., and Tsuchiya, M.
(2007). Elevation of cellular NAD levels by nicotinic acid and involvement of
nicotinic acid phosphoribosyltransferase in human cells. J. Biol. Chem. 282,
24574–24582.
Hara, N., Yamada, K., Shibata, T., Osago, H., and Tsuchiya, M. (2011). Nico-
tinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide
mononucleotide formation in blood plasma. PLoS ONE 6, e22781.
Harden, A., and Young, W.J. (1906). The Alcoholic Ferment of Yeast-Juice.
Part II.–The Conferment of Yeast-Juice. Proc. R. Soc. Lond., B 78, 369–375.
Hasmann, M., and Schemainda, I. (2003). FK866, a highly specific noncom-
petitive inhibitor of nicotinamide phosphoribosyltransferase, represents a
novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63,
7436–7442.
Hassa, P.O., Buerki, C., Lombardi, C., Imhof, R., and Hottiger, M.O. (2003).
Transcriptional coactivation of nuclear factor-kappaB-dependent gene
expression by p300 is regulated by poly(ADP)-ribose polymerase-1. J. Biol.
Chem. 278, 45145–45153.
Hegyi, J., Schwartz, R.A., and Hegyi, V. (2004). Pellagra: dermatitis, dementia,
and diarrhea. Int. J. Dermatol. 43, 1–5.
Henderson, L.M. (1997). Tryptophan’s role as a vitamin precursor (Krehl et al.,
1945). J. Nutr. 127 (Suppl ), 1043S–1045S.
Henderson, L.M., and Gross, C.J. (1979). Metabolism of niacin and niacin-
amide in perfused rat intestine. J. Nutr. 109, 654–662.
Herbert, M., Sauer, E., Smethurst, G., Kraiss, A., Hilpert, A.K., and Reidl, J.
(2003). Nicotinamide ribosyl uptakemutants in Haemophilus influenzae. Infect.
Immun. 71, 5398–5401.
Herranz, D., Mun˜oz-Martin, M., Can˜amero,M., Mulero, F., Martinez-Pastor, B.,
Fernandez-Capetillo, O., and Serrano, M. (2010). Sirt1 improves healthy
ageing and protects from metabolic syndrome-associated cancer. Nat. Com-
mun. 1, 3.
Hikosaka, K., Ikutani, M., Shito, M., Kazuma, K., Gulshan, M., Nagai, Y., Ta-
katsu, K., Konno, K., Tobe, K., Kanno, H., and Nakagawa, T. (2014). Deficiency
of nicotinamidemononucleotide adenylyltransferase 3 (nmnat3) causes hemo-
lytic anemia by altering the glycolytic flow in mature erythrocytes. J. Biol.
Chem. 289, 14796–14811.
Hirschey, M.D., Shimazu, T., Jing, E., Grueter, C.A., Collins, A.M., Aouizerat,
B., Stanca´kova´, A., Goetzman, E., Lam, M.M., Schwer, B., et al. (2011).
SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the
development of the metabolic syndrome. Mol. Cell 44, 177–190.
Ho, C.K., and Hashim, S.A. (1972). Pyridine nucleotide depletion in pancreatic
islets associatedwith streptozotocin-induced diabetes. Diabetes 21, 789–793.
Hong, J., Kim, B.-W., Choo, H.-J., Park, J.-J., Yi, J.-S., Yu, D.-M., Lee, H.,
Yoon, G.-S., Lee, J.-S., and Ko, Y.-G. (2014). Mitochondrial complex I defi-
ciency enhances skeletal myogenesis but impairs insulin signaling through
SIRT1 inactivation. J. Biol. Chem. 289, 20012–20025.
Horwitt, M.K., Harper, A.E., and Henderson, L.M. (1981). Niacin-tryptophan re-
lationships for evaluating niacin equivalents. Am. J. Clin. Nutr. 34, 423–427.
Houtkooper, R.H., Canto´, C., Wanders, R.J., and Auwerx, J. (2010a). The se-
cret life of NAD+: an old metabolite controlling new metabolic signaling path-
ways. Endocr. Rev. 31, 194–223.
Houtkooper, R.H., Williams, R.W., and Auwerx, J. (2010b). Metabolic networks
of longevity. Cell 142, 9–14.
Houtkooper, R.H., Pirinen, E., and Auwerx, J. (2012). Sirtuins as regulators of
metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13, 225–238.
Houtkooper, R.H., Mouchiroud, L., Ryu, D., Moullan, N., Katsyuba, E., Knott,
G., Williams, R.W., and Auwerx, J. (2013). Mitonuclear protein imbalance as
a conserved longevity mechanism. Nature 497, 451–457.
Cell Metabolism
ReviewHu, Y., Wang, H., Wang, Q., and Deng, H. (2014). Overexpression of CD38 de-
creases cellular NAD levels and alters the expression of proteins involved in
energy metabolism and antioxidant defense. J. Proteome Res. 13, 786–795.
Ieraci, A., and Herrera, D.G. (2006). Nicotinamide protects against ethanol-
induced apoptotic neurodegeneration in the developing mouse brain. PLoS
Med. 3, e101.
Ikeda,M., Tsuji, H., Nakamura, S., Ichiyama, A., Nishizuka, Y., and Hayaishi, O.
(1965). STUDIES ON THE BIOSYNTHESIS OF NICOTINAMIDE ADENINE
DINUCLEOTIDE. II. A ROLE OF PICOLINIC CARBOXYLASE IN THE
BIOSYNTHESIS OF NICOTINAMIDE ADENINE DINUCLEOTIDE FROM
TRYPTOPHAN IN MAMMALS. J. Biol. Chem. 240, 1395–1401.
Imai, S., Armstrong, C.M., Kaeberlein, M., and Guarente, L. (2000). Transcrip-
tional silencing and longevity protein Sir2 is anNAD-dependent histone deace-
tylase. Nature 403, 795–800.
Institute of Medicine (US) Standing Committee on the Scientific Evaluation of
Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and
Choline (1998). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin,
Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline (Wash-
ington (DC): National Academies Press (US)).
Jackson, D.G., and Bell, J.I. (1990). Isolation of a cDNA encoding the human
CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontin-
uous pattern of expression during lymphocyte differentiation. J. Immunol.
144, 2811–2815.
Jacobson, E.L. (1993). Niacin deficiency and cancer in women. J. Am. Coll.
Nutr. 12, 412–416.
Jacobson, E.L., Dame, A.J., Pyrek, J.S., and Jacobson, M.K. (1995). Evalu-
ating the role of niacin in human carcinogenesis. Biochimie 77, 394–398.
Jiang, J.C., Jaruga, E., Repnevskaya, M.V., and Jazwinski, S.M. (2000). An
intervention resembling caloric restriction prolongs life span and retards aging
in yeast. FASEB J. 14, 2135–2137.
Jiang, H., Kim, J.H., Frizzell, K.M., Kraus, W.L., and Lin, H. (2010). Clickable
NAD analogues for labeling substrate proteins of poly(ADP-ribose) polymer-
ases. J. Am. Chem. Soc. 132, 9363–9372.
Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., Du, J., Kim,
R., Ge, E., Mostoslavsky, R., et al. (2013). SIRT6 regulates TNF-a secretion
through hydrolysis of long-chain fatty acyl lysine. Nature 496, 110–113.
Kaeberlein, M., McVey, M., and Guarente, L. (1999). The SIR2/3/4 complex
and SIR2 alone promote longevity in Saccharomyces cerevisiae by two
different mechanisms. Genes Dev. 13, 2570–2580.
Kaelin, W.G., Jr., andMcKnight, S.L. (2013). Influence of metabolism on epige-
netics and disease. Cell 153, 56–69.
Kameshita, I., Matsuda, Z., Taniguchi, T., and Shizuta, Y. (1984). Poly (ADP-
Ribose) synthetase. Separation and identification of three proteolytic frag-
ments as the substrate-binding domain, the DNA-binding domain, and the
automodification domain. J. Biol. Chem. 259, 4770–4776.
Kanfi, Y., Naiman, S., Amir, G., Peshti, V., Zinman, G., Nahum, L., Bar-Joseph,
Z., and Cohen, H.Y. (2012). The sirtuin SIRT6 regulates lifespan in male mice.
Nature 483, 218–221.
Kang-Lee, Y.A., McKee, R.W., Wright, S.M., Swendseid, M.E., Jenden, D.J.,
and Jope, R.S. (1983). Metabolic effects of nicotinamide administration in
rats. J. Nutr. 113, 215–221.
Kannt, A., Sicka, K., Kroll, K., Kadereit, D., and Go¨gelein, H. (2012). Selective
inhibitors of cardiac ADPR cyclase as novel anti-arrhythmic compounds. Nau-
nyn Schmiedebergs Arch. Pharmacol. 385, 717–727.
Kellenberger, E., Kuhn, I., Schuber, F., and Muller-Steffner, H. (2011). Flavo-
noids as inhibitors of human CD38. Bioorg. Med. Chem. Lett. 21, 3939–3942.
Khan, N.A., Auranen, M., Paetau, I., Pirinen, E., Euro, L., Forsstrom, S., Pasila,
L., Velagapudi, V., Carroll, C.J., Auwerx, J., et al. (2014). Effective treatment of
mitochondrial myopathy by nicotinamide riboside, a vitamin B3 (EMBO Mol
Med).
Klaidman, L., Morales, M., Kem, S., Yang, J., Chang, M.-L., and Adams, J.D.,
Jr. (2003). Nicotinamide offers multiple protective mechanisms in stroke as a
precursor for NAD+, as a PARP inhibitor and by partial restoration ofmitochon-
drial function. Pharmacology 69, 150–157.Kolthur-Seetharam, U., Dantzer, F., McBurney, M.W., de Murcia, G., and Sas-
sone-Corsi, P. (2006). Control of AIF-mediated cell death by the functional
interplay of SIRT1 and PARP-1 in response to DNA damage. Cell Cycle 5,
873–877.
Kraus, W.L., and Hottiger, M.O. (2013). PARP-1 and gene regulation: progress
and puzzles. Mol. Aspects Med. 34, 1109–1123.
Kraus, D., Yang, Q., Kong, D., Banks, A.S., Zhang, L., Rodgers, J.T., Pirinen,
E., Pulinilkunnil, T.C., Gong, F., Wang, Y.C., et al. (2014). Nicotinamide
N-methyltransferase knockdown protects against diet-induced obesity.
Nature 508, 258–262.
Kumar, S., and Lombard, D.B. (2015). Mitochondrial sirtuins and their relation-
ships with metabolic disease and cancer. Antioxid. Redox Signaling 22, 1060–
1077.
Lamming, D.W., Latorre-Esteves, M., Medvedik, O., Wong, S.N., Tsang, F.A.,
Wang, C., Lin, S.-J., and Sinclair, D.A. (2005). HST2 mediates SIR2-indepen-
dent life-span extension by calorie restriction. Science 309, 1861–1864.
Langley, E., Pearson, M., Faretta, M., Bauer, U.-M., Frye, R.A., Minucci, S.,
Pelicci, P.G., and Kouzarides, T. (2002). Human SIR2 deacetylates p53 and
antagonizes PML/p53-induced cellular senescence. EMBO J. 21, 2383–2396.
Lau, C., Niere, M., and Ziegler, M. (2009). The NMN/NaMN adenylyltransferase
(NMNAT) protein family. Front Biosci (Landmark Ed) 14, 410–431.
Laurent, G., German, N.J., Saha, A.K., de Boer, V.C., Davies, M., Koves, T.R.,
Dephoure, N., Fischer, F., Boanca, G., Vaitheesvaran, B., et al. (2013). SIRT4
coordinates the balance between lipid synthesis and catabolism by repressing
malonyl CoA decarboxylase. Mol. Cell 50, 686–698.
Lauring, B., Taggart, A.K.P., Tata, J.R., Dunbar, R., Caro, L., Cheng, K., Chin,
J., Colletti, S.L., Cote, J., Khalilieh, S., et al. (2012). Niacin lipid efficacy is inde-
pendent of both the niacin receptor GPR109A and free fatty acid suppression.
Sci. Transl. Med. 4, http://dx.doi.org/10.1126/scitranslmed.3003877.
Lee, H.C. (2012). Cyclic ADP-ribose and nicotinic acid adenine dinucleotide
phosphate (NAADP) as messengers for calcium mobilization. J. Biol. Chem.
287, 31633–31640.
Lehmann, M., Pirinen, E., Mirsaidi, A., Kunze, F.A., Richards, P.J., Auwerx, J.,
and Hottiger, M.O. (2015). ARTD1-induced poly-ADP-ribose formation en-
hances PPARg ligand binding and co-factor exchange. Nucleic Acids Res.
43, 129–142.
Li, X., Millar, J.S., Brownell, N., Briand, F., and Rader, D.J. (2010). Modulation
of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.
Biochem. Pharmacol. 80, 1450–1457.
Lin, S.-J., Ford, E., Haigis, M., Liszt, G., and Guarente, L. (2004). Calorie re-
striction extends yeast life span by lowering the level of NADH. Genes Dev.
18, 12–16.
Liszt, G., Ford, E., Kurtev, M., and Guarente, L. (2005). Mouse Sir2 homolog
SIRT6 is a nuclear ADP-ribosyltransferase. J. Biol. Chem. 280, 21313–21320.
Llopis, J., Westin, S., Ricote, M., Wang, Z., Cho, C.Y., Kurokawa, R., Mullen,
T.M., Rose, D.W., Rosenfeld, M.G., Tsien, R.Y., and Glass, C.K. (2000).
Ligand-dependent interactions of coactivators steroid receptor coactivator-
1 and peroxisome proliferator-activated receptor binding protein with nuclear
hormone receptors can be imaged in live cells and are required for transcrip-
tion. Proc. Natl. Acad. Sci. USA 97, 4363–4368.
Lu, S.-P., Kato, M., and Lin, S.-J. (2009). Assimilation of endogenous nicotin-
amide riboside is essential for calorie restriction-mediated life span extension
in Saccharomyces cerevisiae. J. Biol. Chem. 284, 17110–17119.
Luo, J., Nikolaev, A.Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L., and
Gu, W. (2001). Negative control of p53 by Sir2alpha promotes cell survival
under stress. Cell 107, 137–148.
Mack, T.G., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D.,
Thomson, D., Gillingwater, T., Court, F., Conforti, L., et al. (2001). Wallerian
degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat
chimeric gene. Nat. Neurosci. 4, 1199–1206.
Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A.L., Ortolan, E.,
Vaisitti, T., and Aydin, S. (2008). Evolution and function of the ADP ribosyl
cyclase/CD38 gene family in physiology and pathology. Physiol. Rev. 88,
841–886.Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 49
Cell Metabolism
ReviewMao, Z., Hine, C., Tian, X., VanMeter, M., Au, M., Vaidya, A., Seluanov, A., and
Gorbunova, V. (2011). SIRT6 promotes DNA repair under stress by activating
PARP1. Science 332, 1443–1446.
Massudi, H., Grant, R., Braidy, N., Guest, J., Farnsworth, B., and Guillemin,
G.J. (2012). Age-associated changes in oxidative stress and NAD+ meta-
bolism in human tissue. PLoS ONE 7, e42357.
Masutani, M., Suzuki, H., Kamada, N., Watanabe, M., Ueda, O., Nozaki, T.,
Jishage, K., Watanabe, T., Sugimoto, T., Nakagama, H., et al. (1999).
Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to
streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA 96, 2301–2304.
Mathias, R.A., Greco, T.M., Oberstein, A., Budayeva, H.G., Chakrabarti, R.,
Rowland, E.A., Kang, Y., Shenk, T., and Cristea, I.M. (2014). Sirtuin 4 is a lip-
oamidase regulating pyruvate dehydrogenase complex activity. Cell 159,
1615–1625.
McKenna, M.C., Waagepetersen, H.S., Schousboe, A., and Sonnewald, U.
(2006). Neuronal and astrocytic shuttle mechanisms for cytosolic-mitochon-
drial transfer of reducing equivalents: current evidence and pharmacological
tools. Biochem. Pharmacol. 71, 399–407.
Mendoza-Alvarez, H., and Alvarez-Gonzalez, R. (1993). Poly(ADP-ribose)
polymerase is a catalytic dimer and the automodification reaction is intermo-
lecular. J. Biol. Chem. 268, 22575–22580.
Menzies, K.J., Singh, K., Saleem, A., andHood, D.A. (2013). Sirtuin 1-mediated
effects of exercise and resveratrol on mitochondrial biogenesis. J. Biol. Chem.
288, 6968–6979.
Mercken, E.M., Hu, J., Krzysik-Walker, S., Wei, M., Li, Y., McBurney, M.W., de
Cabo, R., and Longo, V.D. (2013). SIRT1 but not its increased expression is
essential for lifespan extension in caloric restricted mice. Aging Cell 13,
193–196.
Michishita, E., Park, J.Y., Burneskis, J.M., Barrett, J.C., and Horikawa, I.
(2005). Evolutionarily conserved and nonconserved cellular localizations and
functions of human SIRT proteins. Mol. Biol. Cell 16, 4623–4635.
Minor, R.K., Baur, J.A., Gomes, A.P., Ward, T.M., Csiszar, A., Mercken, E.M.,
Abdelmohsen, K., Shin, Y.K., Canto, C., Scheibye-Knudsen, M., et al. (2011).
SRT1720 improves survival and healthspan of obese mice. Sci. Rep. 1, 70.
Mostoslavsky, R., Chua, K.F., Lombard, D.B., Pang, W.W., Fischer, M.R., Gel-
lon, L., Liu, P., Mostoslavsky, G., Franco, S., Murphy, M.M., et al. (2006).
Genomic instability and aging-like phenotype in the absence of mammalian
SIRT6. Cell 124, 315–329.
Mouchiroud, L., Houtkooper, R.H., Moullan, N., Katsyuba, E., Ryu, D., Canto´,
C., Mottis, A., Jo, Y.-S., Viswanathan, M., Schoonjans, K., et al. (2013). The
NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochon-
drial UPR and FOXO Signaling. Cell 154, 430–441.
Mukhopadhyay, P., Rajesh, M., Cao, Z., Horva´th, B., Park, O., Wang, H.,
Erdelyi, K., Holovac, E., Wang, Y., Liaudet, L., et al. (2014). Poly (ADP-ribose)
polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology
59, 1998–2009.
Nakagawa, T., Lomb, D.J., Haigis, M.C., and Guarente, L. (2009). SIRT5 De-
acetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle.
Cell 137, 560–570.
Nakahata, Y., Kaluzova, M., Grimaldi, B., Sahar, S., Hirayama, J., Chen, D.,
Guarente, L.P., and Sassone-Corsi, P. (2008). The NAD+-dependent deacety-
lase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian
control. Cell 134, 329–340.
Nakahata, Y., Sahar, S., Astarita, G., Kaluzova, M., and Sassone-Corsi, P.
(2009). Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Sci-
ence 324, 654–657.
Nam, T.-S., Choi, S.H., Rah, S.-Y., Kim, S.-Y., Jang, W., Im, M.-J., Kwon, H.J.,
and Kim, U.-H. (2006). Discovery of a small-molecule inhibitor for kidney ADP-
ribosyl cyclase: Implication for intracellular calcium signal mediated by cyclic
ADP-ribose. Exp. Mol. Med. 38, 718–726.
Nikiforov, A., Do¨lle, C., Niere, M., and Ziegler, M. (2011). Pathways and subcel-
lular compartmentation of NAD biosynthesis in human cells: from entry of
extracellular precursors to mitochondrial NAD generation. J. Biol. Chem.
286, 21767–21778.50 Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc.North, B.J., Marshall, B.L., Borra, M.T., Denu, J.M., and Verdin, E. (2003). The
human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol.
Cell 11, 437–444.
Olmos, P.R., Hodgson, M.I., Maiz, A., Manrique, M., De Valde´s, M.D., Foncea,
R., Acosta, A.M., Emmerich, M.V., Velasco, S., Mun˜iz, O.P., et al. (2006). Nico-
tinamide protected first-phase insulin response (FPIR) and prevented clinical
disease in first-degree relatives of type-1 diabetics. Diabetes Res. Clin. Pract.
71, 320–333.
Owusu-Ansah, E., Song, W., and Perrimon, N. (2013). Muscle mitohormesis
promotes longevity via systemic repression of insulin signaling. Cell 155,
699–712.
Pacholec, M., Bleasdale, J.E., Chrunyk, B., Cunningham, D., Flynn, D., Garo-
falo, R.S., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., et al. (2010). SRT1720,
SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol.
Chem. 285, 8340–8351.
Pan, P.W., Feldman, J.L., Devries, M.K., Dong, A., Edwards, A.M., and Denu,
J.M. (2011). Structure and biochemical functions of SIRT6. J. Biol. Chem. 286,
14575–14587.
Pearson, K.J., Baur, J.A., Lewis, K.N., Peshkin, L., Price, N.L., Labinskyy, N.,
Swindell, W.R., Kamara, D., Minor, R.K., Perez, E., et al. (2008). Resveratrol
delays age-related deterioration and mimics transcriptional aspects of dietary
restriction without extending life span. Cell Metab. 8, 157–168.
Petesch, S.J., and Lis, J.T. (2012). Activator-induced spread of poly(ADP-
ribose) polymerase promotes nucleosome loss at Hsp70. Mol. Cell 45, 64–74.
Pfluger, P.T., Herranz, D., Velasco-Miguel, S., Serrano, M., and Tscho¨p, M.H.
(2008). Sirt1 protects against high-fat diet-induced metabolic damage. Proc.
Natl. Acad. Sci. USA 105, 9793–9798.
Pieper, A.A., Xie, S., Capota, E., Estill, S.J., Zhong, J., Long, J.M., Becker, G.L.,
Huntington, P., Goldman, S.E., Shen, C.-H., et al. (2010). Discovery of a pro-
neurogenic, neuroprotective chemical. Cell 142, 39–51.
Pillai, J.B., Isbatan, A., Imai, S.-i., and Gupta, M.P. (2005). Poly(ADP-ribose)
polymerase-1-dependent cardiac myocyte cell death during heart failure is
mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity.
J. Biol. Chem. 280, 43121–43130.
Pirinen, E., Canto´, C., Jo, Y.S., Morato, L., Zhang, H., Menzies, K.J., Williams,
E.G., Mouchiroud, L., Moullan, N., Hagberg, C., et al. (2014). Pharmacological
Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochon-
drial function in skeletal muscle. Cell Metab. 19, 1034–1041.
Pittelli, M., Formentini, L., Faraco, G., Lapucci, A., Rapizzi, E., Cialdai, F.,
Romano, G., Moneti, G., Moroni, F., and Chiarugi, A. (2010). Inhibition of nico-
tinamide phosphoribosyltransferase: cellular bioenergetics reveals a mito-
chondrial insensitive NAD pool. J. Biol. Chem. 285, 34106–34114.
Pittelli, M., Felici, R., Pitozzi, V., Giovannelli, L., Bigagli, E., Cialdai, F., Romano,
G., Moroni, F., and Chiarugi, A. (2011). Pharmacological effects of exogenous
NAD on mitochondrial bioenergetics, DNA repair, and apoptosis. Mol. Phar-
macol. 80, 1136–1146.
Price, N.L., Gomes, A.P., Ling, A.J.Y., Duarte, F.V., Martin-Montalvo, A., North,
B.J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J.S., et al. (2012). SIRT1 is
required for AMPK activation and the beneficial effects of resveratrol on mito-
chondrial function. Cell Metab. 15, 675–690.
Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., Zhao, W., Thiyagar-
ajan, M., MacGrogan, D., Rodgers, J.T., et al. (2006). Neuronal SIRT1 activa-
tion as a novel mechanism underlying the prevention of Alzheimer disease
amyloid neuropathology by calorie restriction. J. Biol. Chem. 281, 21745–
21754.
Quarona, V., Zaccarello, G., Chillemi, A., Brunetti, E., Singh, V.K., Ferrero, E.,
Funaro, A., Horenstein, A.L., and Malavasi, F. (2013). CD38 and CD157: a long
journey from activation markers to multifunctional molecules. Cytometry B
Clin. Cytom. 84, 207–217.
Rajamohan, S.B., Pillai, V.B., Gupta, M., Sundaresan, N.R., Birukov, K.G.,
Samant, S., Hottiger, M.O., and Gupta, M.P. (2009). SIRT1 promotes cell sur-
vival under stress by deacetylation-dependent deactivation of poly(ADP-
ribose) polymerase 1. Mol. Cell. Biol. 29, 4116–4129.
Ramsey, K.M., Mills, K.F., Satoh, A., and Imai, S. (2008). Age-associated loss
of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta
cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell 7, 78–88.
Cell Metabolism
ReviewRamsey, K.M., Yoshino, J., Brace, C.S., Abrassart, D., Kobayashi, Y., Mar-
cheva, B., Hong, H.K., Chong, J.L., Buhr, E.D., Lee, C., et al. (2009). Circadian
clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science
324, 651–654.
Revollo, J.R., Grimm, A.A., and Imai, S.-i. (2004). The NAD biosynthesis
pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2
activity in mammalian cells. J. Biol. Chem. 279, 50754–50763.
Revollo, J.R., Ko¨rner, A., Mills, K.F., Satoh, A., Wang, T., Garten, A., Dasgupta,
B., Sasaki, Y., Wolberger, C., Townsend, R.R., et al. (2007). Nampt/PBEF/Vis-
fatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic
enzyme. Cell Metab. 6, 363–375.
Riederer, M., Erwa, W., Zimmermann, R., Frank, S., and Zechner, R. (2009).
Adipose tissue as a source of nicotinamide N-methyltransferase and homo-
cysteine. Atherosclerosis 204, 412–417.
Rippmann, J.F., Damm, K., and Schnapp, A. (2002). Functional characteriza-
tion of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential
regulator of telomere length. J. Mol. Biol. 323, 217–224.
Rodgers, J.T., Lerin, C., Haas, W., Gygi, S.P., Spiegelman, B.M., and Puig-
server, P. (2005). Nutrient control of glucose homeostasis through a complex
of PGC-1alpha and SIRT1. Nature 434, 113–118.
Rogina, B., and Helfand, S.L. (2004). Sir2 mediates longevity in the fly through
a pathway related to calorie restriction. Proc. Natl. Acad. Sci. USA 101, 15998–
16003.
Rongvaux, A., Shea, R.J., Mulks, M.H., Gigot, D., Urbain, J., Leo, O., and
Andris, F. (2002). Pre-B-cell colony-enhancing factor, whose expression is
up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyl-
transferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol.
32, 3225–3234.
Ryall, J.G., Dell’Orso, S., Derfoul, A., Juan, A., Zare, H., Feng, X., Clermont, D.,
Koulnis, M., Gutierrez-Cruz, G., Fulco, M., et al. (2015). The NAD+-dependent
SIRT1 deacetylase translates a metabolic switch into regulatory epigenetics in
skeletal muscle stem cells. Cell Stem Cell 16, 171–183.
Ryu, D., Jo, Y.S., Lo Sasso, G., Stein, S., Zhang, H., Perino, A., Lee, J.U., Ze-
viani, M., Romand, R., Hottiger, M.O., et al. (2014). A SIRT7-dependent acet-
ylation switch of GABPb1 controls mitochondrial function. Cell Metab. 20,
856–869.
Sadanaga-Akiyoshi, F., Yao, H., Tanuma, S.-i., Nakahara, T., Hong, J.S.,
Ibayashi, S., Uchimura, H., and Fujishima, M. (2003). Nicotinamide attenuates
focal ischemic brain injury in rats: with special reference to changes in nicotin-
amide and NAD+ levels in ischemic core and penumbra. Neurochem. Res. 28,
1227–1234.
Sajish, M., and Schimmel, P. (2015). A human tRNA synthetase is a potent
PARP1-activating effector target for resveratrol. Nature 519, 370–373.
Sasaki, Y., Araki, T., and Milbrandt, J. (2006). Stimulation of nicotinamide
adenine dinucleotide biosynthetic pathways delays axonal degeneration after
axotomy. J. Neurosci. 26, 8484–8491.
Sasaki, Y., Vohra, B.P.S., Lund, F.E., and Milbrandt, J. (2009). Nicotinamide
mononucleotide adenylyl transferase-mediated axonal protection requires
enzymatic activity but not increased levels of neuronal nicotinamide adenine
dinucleotide. J. Neurosci. 29, 5525–5535.
Satoh, A., Brace, C.S., Rensing, N., Cliften, P., Wozniak, D.F., Herzog, E.D.,
Yamada, K.A., and Imai, S.-i. (2013). Sirt1 extends life span and delays aging
in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell
Metab. 18, 416–430.
Sauve, A.A., Munshi, C., Lee, H.C., and Schramm, V.L. (1998). The reaction
mechanism for CD38. A single intermediate is responsible for cyclization, hy-
drolysis, and base-exchange chemistries. Biochemistry 37, 13239–13249.
Scheibye-Knudsen, M., Fang, E.F., Croteau, D.L., and Bohr, V.A. (2014).
Contribution of defective mitophagy to the neurodegeneration in DNA repair-
deficient disorders. Autophagy 10, 1468–1469.
Schein, P.S., Cooney, D.A., and Vernon, M.L. (1967). The use of nicotinamide
to modify the toxicity of streptozotocin diabetes without loss of antitumor ac-
tivity. Cancer Res. 27, 2324–2332.
Schmeisser, K., Mansfeld, J., Kuhlow, D., Weimer, S., Priebe, S., Heiland, I.,
Birringer, M., Groth, M., Segref, A., Kanfi, Y., et al. (2013). Role of sirtuins in life-span regulation is linked to methylation of nicotinamide. Nat. Chem. Biol. 9,
693–700.
Schmidt, M.T., Smith, B.C., Jackson, M.D., and Denu, J.M. (2004). Coenzyme
specificity of Sir2 protein deacetylases: implications for physiological regula-
tion. J. Biol. Chem. 279, 40122–40129.
Schwer, B., North, B.J., Frye, R.A., Ott, M., and Verdin, E. (2002). The human
silent information regulator (Sir)2 homologue hSIRT3 is amitochondrial nicotin-
amide adenine dinucleotide-dependent deacetylase. J. Cell Biol. 158,
647–657.
Seal, A.J., Creeke, P.I., Dibari, F., Cheung, E., Kyroussis, E., Semedo, P., and
van den Briel, T. (2007). Low and deficient niacin status and pellagra are
endemic in postwar Angola. Am. J. Clin. Nutr. 85, 218–224.
Smith, B.C., Hallows, W.C., and Denu, J.M. (2009). A continuous microplate
assay for sirtuins and nicotinamide-producing enzymes. Anal. Biochem. 394,
101–109.
Soga, T., Kamohara, M., Takasaki, J., Matsumoto, S., Saito, T., Ohishi, T.,
Hiyama, H., Matsuo, A., Matsushime, H., and Furuichi, K. (2003). Molecular
identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun.
303, 364–369.
Someya, S., Yu, W., Hallows, W.C., Xu, J., Vann, J.M., Leeuwenburgh, C., Ta-
nokura, M., Denu, J.M., and Prolla, T.A. (2010). Sirt3 mediates reduction of
oxidative damage and prevention of age-related hearing loss under caloric re-
striction. Cell 143, 802–812.
Stein, L.R., and Imai, S.-i. (2014). Specific ablation of Nampt in adult neural
stem cells recapitulates their functional defects during aging. EMBO J. 33,
1321–1340.
Stone, T.W., and Darlington, L.G. (2002). Endogenous kynurenines as targets
for drug discovery and development. Nat. Rev. Drug Discov. 1, 609–620.
Sydenstricker, V.P. (1958). The history of pellagra, its recognition as a disorder
of nutrition and its conquest. Am. J. Clin. Nutr. 6, 409–414.
Szczesny, B., Brunya´nszki, A., Olah, G., Mitra, S., and Szabo, C. (2014).
Opposing roles of mitochondrial and nuclear PARP1 in the regulation of mito-
chondrial and nuclear DNA integrity: implications for the regulation of mito-
chondrial function. Nucleic Acids Res. 42, 13161–13173.
Tan, M., Peng, C., Anderson, K.A., Chhoy, P., Xie, Z., Dai, L., Park, J., Chen, Y.,
Huang, H., Zhang, Y., et al. (2014). Lysine glutarylation is a protein posttrans-
lational modification regulated by SIRT5. Cell Metab. 19, 605–617.
Tanno, M., Sakamoto, J., Miura, T., Shimamoto, K., and Horio, Y. (2007). Nu-
cleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1.
J. Biol. Chem. 282, 6823–6832.
Tesla, R., Wolf, H.P., Xu, P., Drawbridge, J., Estill, S.J., Huntington, P.,
McDaniel, L., Knobbe, W., Burket, A., Tran, S., et al. (2012). Neuroprotective
efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral
sclerosis. Proc. Natl. Acad. Sci. USA 109, 17016–17021.
Tissenbaum, H.A., and Guarente, L. (2001). Increased dosage of a sir-2 gene
extends lifespan in Caenorhabditis elegans. Nature 410, 227–230.
Tummala, K.S., Gomes, A.L., Yilmaz, M., Gran˜a, O., Bakiri, L., Ruppen, I., Xi-
me´nez-Embu´n, P., Sheshappanavar, V., Rodriguez-Justo, M., Pisano, D.G.,
et al. (2014). Inhibition of de novo NAD(+) synthesis by oncogenic URI causes
liver tumorigenesis through DNA damage. Cancer Cell 26, 826–839.
Tunaru, S., Kero, J., Schaub, A., Wufka, C., Blaukat, A., Pfeffer, K., and Offer-
manns, S. (2003). PUMA-G and HM74 are receptors for nicotinic acid and
mediate its anti-lipolytic effect. Nat. Med. 9, 352–355.
Turunc Bayrakdar, E., Armagan, G., Uyanikgil, Y., Kanit, L., Koylu, E., and Yal-
cin, A. (2014a). Ex vivo protective effects of nicotinamide and 3-aminobenza-
mide on rat synaptosomes treated with Ab(1-42). Cell Biochem. Funct. 32,
557–564.
Turunc Bayrakdar, E., Uyanikgil, Y., Kanit, L., Koylu, E., and Yalcin, A. (2014b).
Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and
PARP-1 activity in Ab(1-42)-induced rat model of Alzheimer’s disease. Free
Radic. Res. 48, 146–158.
Upadhya, R., Lee, J., and Willis, I.M. (2002). Maf1 is an essential mediator of
diverse signals that repress RNA polymerase III transcription. Mol. Cell 10,
1489–1494.Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 51
Cell Metabolism
ReviewVakhrusheva, O., Smolka, C., Gajawada, P., Kostin, S., Boettger, T., Kubin, T.,
Braun, T., and Bober, E. (2008). Sirt7 increases stress resistance of cardio-
myocytes and prevents apoptosis and inflammatory cardiomyopathy in
mice. Circ. Res. 102, 703–710.
Valenzuela, M.T., Guerrero, R., Nu´n˜ez, M.I., Ruiz De Almodo´var, J.M., Sarker,
M., deMurcia, G., andOliver, F.J. (2002). PARP-1modifies the effectiveness of
p53-mediated DNA damage response. Oncogene 21, 1108–1116.
Van Beijnum, J.R., Moerkerk, P.T.M., Gerbers, A.J., De Bruı¨ne, A.P., Arends,
J.-W., Hoogenboom, H.R., and Hufton, S.E. (2002). Target validation for geno-
mics using peptide-specific phage antibodies: a study of five gene products
overexpressed in colorectal cancer. Int. J. Cancer 101, 118–127.
van deWeijer, T., Phielix, E., Bilet, L., Williams, E.G., Ropelle, E.R., Bierwagen,
A., Livingstone, R., Nowotny, P., Sparks, L.M., Paglialunga, S., et al. (2014).
Evidence for a direct effect of the NAD+ precursor Acipimox on muscle mito-
chondrial function in humans. Diabetes 64, 1193–1201.
van Roermund, C.W., Elgersma, Y., Singh, N., Wanders, R.J., and Tabak, H.F.
(1995). The membrane of peroxisomes in Saccharomyces cerevisiae is imper-
meable to NAD(H) and acetyl-CoA under in vivo conditions. EMBOJ. 14, 3480–
3486.
Vaziri, H., Dessain, S.K., Ng Eaton, E., Imai, S.I., Frye, R.A., Pandita, T.K.,
Guarente, L., and Weinberg, R.A. (2001). hSIR2(SIRT1) functions as an NAD-
dependent p53 deacetylase. Cell 107, 149–159.
Verdin, E., Hirschey,M.D., Finley, L.W.S., and Haigis, M.C. (2010). Sirtuin regu-
lation of mitochondria: energy production, apoptosis, and signaling. Trends
Biochem. Sci. 35, 669–675.
Wang, R.-H., Sengupta, K., Li, C., Kim, H.-S., Cao, L., Xiao, C., Kim, S., Xu,
X., Zheng, Y., Chilton, B., et al. (2008). Impaired DNA damage response,
genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell
14, 312–323.
Wang, B., Hasan, M.K., Alvarado, E., Yuan, H., Wu, H., and Chen, W.Y. (2011).
NAMPT overexpression in prostate cancer and its contribution to tumor cell
survival and stress response. Oncogene 30, 907–921.
Wang, J.T., Medress, Z.A., and Barres, B.A. (2012). Axon degeneration: mo-
lecular mechanisms of a self-destruction pathway. J. Cell Biol. 196, 7–18.
Wang, G., Han, T., Nijhawan, D., Theodoropoulos, P., Naidoo, J., Yadavalli, S.,
Mirzaei, H., Pieper, A.A., Ready, J.M., and McKnight, S.L. (2014a). P7C3 neu-
roprotective chemicals function by activating the rate-limiting enzyme in NAD
salvage. Cell 158, 1324–1334.
Wang, L., Ding, D., Salvi, R., and Roth, J.A. (2014b). Nicotinamide adenine
dinucleotide prevents neuroaxonal degeneration induced by manganese in
cochlear organotypic cultures. Neurotoxicology 40, 65–74.
Warburg, O., Christian, W., and Griese, A. (1935). Hydrogen-transferring co-
enzyme, its composition and mode of functioning. Biochem. Z. 280,
157–205.
Watson, M., Roulston, A., Be´lec, L., Billot, X., Marcellus, R., Be´dard, D., Ber-
nier, C., Branchaud, S., Chan, H., Dairi, K., et al. (2009). The small molecule
GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced
therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors. Mol.
Cell. Biol. 29, 5872–5888.
Williams, A.C., and Dunbar, R.I.M. (2014). Big brains, meat, tuberculosis and
the nicotinamide switches: co-evolutionary relationships with modern reper-
cussions on longevity and disease? Med. Hypotheses 83, 79–87.
Wise, A., Foord, S.M., Fraser, N.J., Barnes, A.A., Elshourbagy, N., Eilert, M.,
Ignar, D.M., Murdock, P.R., Steplewski, K., Green, A., et al. (2003). Molecular
identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem.
278, 9869–9874.
Wu, J., Zhang, F., Yan, M., Wu, D., Yu, Q., Zhang, Y., Zhou, B., McBurney,
M.W., and Zhai, Q. (2011). WldS enhances insulin transcription and secretion
via a SIRT1-dependent pathway and improves glucose homeostasis. Diabetes
60, 3197–3207.
Wu, Y., Williams, E.G., Dubuis, S., Mottis, A., Jovaisaite, V., Houten, S.M., Arg-
mann, C.A., Faridi, P., Wolski, W., Kutalik, Z., et al. (2014). Multilayered genetic
and omics dissection of mitochondrial activity in a mouse reference popula-
tion. Cell 158, 1415–1430.52 Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc.Xie, G.-H., Rah, S.-Y., Kim, S.J., Nam, T.-S., Ha, K.-C., Chae, S.-W., Im, M.-J.,
and Kim, U.-H. (2005). ADP-ribosyl cyclase couples to cyclic AMP signaling in
the cardiomyocytes. Biochem. Biophys. Res. Commun. 330, 1290–1298.
Yahata, N., Yuasa, S., and Araki, T. (2009). Nicotinamide mononucleotide ad-
enylyltransferase expression in mitochondrial matrix delays Wallerian degen-
eration. J. Neurosci. 29, 6276–6284.
Yalowitz, J.A., Xiao, S., Biju, M.P., Antony, A.C., Cummings, O.W., Deeg, M.A.,
and Jayaram, H.N. (2004). Characterization of human brain nicotinamide 50-
mononucleotide adenylyltransferase-2 and expression in human pancreas.
Biochem. J. 377, 317–326.
Yamamoto, H., Uchigata, Y., and Okamoto, H. (1981). Streptozotocin and
alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancre-
atic islets. Nature 294, 284–286.
Yan, T., Feng, Y., Zheng, J., Ge, X., Zhang, Y., Wu, D., Zhao, J., and Zhai, Q.
(2010). Nmnat2 delays axon degeneration in superior cervical ganglia depen-
dent on its NAD synthesis activity. Neurochem. Int. 56, 101–106.
Yang, H., Yang, T., Baur, J.A., Perez, E., Matsui, T., Carmona, J.J., Lamming,
D.W., Souza-Pinto, N.C., Bohr, V.A., Rosenzweig, A., et al. (2007a). Nutrient-
sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130, 1095–
1107.
Yang, T., Chan, N.Y., and Sauve, A.A. (2007b). Syntheses of nicotinamide ribo-
side and derivatives: effective agents for increasing nicotinamide adenine
dinucleotide concentrations in mammalian cells. J. Med. Chem. 50, 6458–
6461.
Yang, S.J., Choi, J.M., Kim, L., Park, S.E., Rhee, E.J., Lee, W.Y., Oh, K.W.,
Park, S.W., and Park, C.-Y. (2014). Nicotinamide improves glucose meta-
bolism and affects the hepatic NAD-sirtuin pathway in a rodent model of
obesity and type 2 diabetes. J. Nutr. Biochem. 25, 66–72.
Yeung, F., Hoberg, J.E., Ramsey, C.S., Keller, M.D., Jones, D.R., Frye, R.A.,
and Mayo, M.W. (2004). Modulation of NF-kappaB-dependent transcription
and cell survival by the SIRT1 deacetylase. EMBO J. 23, 2369–2380.
Yin, T.C., Britt, J.K., De Jesu´s-Corte´s, H., Lu, Y., Genova, R.M., Khan, M.Z.,
Voorhees, J.R., Shao, J., Katzman, A.C., Huntington, P.J., et al. (2014).
P7C3 neuroprotective chemicals block axonal degeneration and preserve
function after traumatic brain injury. Cell Rep. 8, 1731–1740.
Ying, W. (2008). NAD+/NADH and NADP+/NADPH in cellular functions and
cell death: regulation and biological consequences. Antioxid. Redox Signal.
10, 179–206.
Ying, W., Alano, C.C., Garnier, P., and Swanson, R.A. (2005). NAD+ as a meta-
bolic link between DNA damage and cell death. J. Neurosci. Res. 79, 216–223.
Yoon, M.J., Yoshida, M., Johnson, S., Takikawa, A., Usui, I., Tobe, K., Naka-
gawa, T., Yoshino, J., and Imai, S.-i. (2015). SIRT1-Mediated eNAMPT Secre-
tion from Adipose Tissue Regulates Hypothalamic NAD(+) and Function in
Mice. Cell Metab. 21, 706–717.
Yoshino, J., Mills, K.F., Yoon, M.J., and Imai, S. (2011). Nicotinamide mononu-
cleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and
age-induced diabetes in mice. Cell Metab. 14, 528–536.
Yu, J., Sadhukhan, S., Noriega, L.G., Moullan, N., He, B., Weiss, R.S., Lin, H.,
Schoonjans, K., and Auwerx, J. (2013). Metabolic characterization of a Sirt5
deficient mouse model. Sci. Rep. 3, http://dx.doi.org/10.1038/srep02806.
Zhang, Q., Piston, D.W., andGoodman, R.H. (2002). Regulation of corepressor
function by nuclear NADH. Science 295, 1895–1897.
Zhang, X., Kurnasov, O.V., Karthikeyan, S., Grishin, N.V., Osterman, A.L., and
Zhang, H. (2003). Structural characterization of a human cytosolic NMN/NaMN
adenylyltransferase and implication in human NAD biosynthesis. J. Biol.
Chem. 278, 13503–13511.
Zhang, Y., Schmidt, R.J., Foxworthy, P., Emkey, R., Oler, J.K., Large, T.H.,
Wang, H., Su, E.W., Mosior, M.K., Eacho, P.I., and Cao, G. (2005). Niacin me-
diates lipolysis in adipose tissue through its G-protein coupled receptor
HM74A. Biochem. Biophys. Res. Commun. 334, 729–732.
Zhang, T., Berrocal, J.G., Frizzell, K.M., Gamble,M.J., DuMond,M.E., Krishna-
kumar, R., Yang, T., Sauve, A.A., and Kraus,W.L. (2009). Enzymes in the NAD+
salvage pathway regulate SIRT1 activity at target gene promoters. J. Biol.
Chem. 284, 20408–20417.
Cell Metabolism
ReviewZhang, L.Q., Heruth, D.P., and Ye, S.Q. (2011). Nicotinamide phosphoribosyl-
transferase in human diseases. J. Bioanal. Biomed. 3, 13–25.
Zhang, T., Berrocal, J.G., Yao, J., DuMond, M.E., Krishnakumar, R., Ruhl,
D.D., Ryu, K.W., Gamble, M.J., and Kraus, W.L. (2012). Regulation of
poly(ADP-ribose) polymerase-1-dependent gene expression through pro-
moter-directed recruitment of a nuclear NAD+ synthase. J. Biol. Chem. 287,
12405–12416.
Zhang, F., Xie, R., Munoz, F.M., Lau, S.S., and Monks, T.J. (2014). PARP-1
hyperactivation and reciprocal elevations in intracellular Ca2+ during ros-
induced nonapoptotic cell death. Toxicol Sci. 140, 118–134.Zhao, Y.J., Lam, C.M.C., and Lee, H.C. (2012). The membrane-bound enzyme
CD38 exists in two opposing orientations. Sci. Signal. 5, ra67.
Zhong, L., D’Urso, A., Toiber, D., Sebastian, C., Henry, R.E., Vadysirisack,
D.D., Guimaraes, A., Marinelli, B., Wikstrom, J.D., Nir, T., et al. (2010). The his-
tone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 140,
280–293.
Zhou, M., Ottenberg, G., Sferrazza, G.F., Hubbs, C., Fallahi, M., Rumbaugh,
G., Brantley, A.F., and Lasme´zas, C.I. (2015). Neuronal death induced by
misfolded prion protein is due to NAD+ depletion and can be relieved in vitro
and in vivo by NAD+ replenishment. Brain 138, 992–1008.Cell Metabolism 22, July 7, 2015 ª2015 Elsevier Inc. 53
